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Introduction 
From a broad sustainable development viewpoint, intellectual property (IP) might relate to a 
number of aspects of a country’s social and economic development. Its impact can be felt in 
industrial, health, education, nutrition, biodiversity and cultural policies. In exploring the issues 
relating to sustainable development and the important changes that have taken place in the IP 
landscape, we will focus on issues that are drawing particular attention in major international for 
and to developments that are taking place in bilateral trade negotiations. 
This paper will thus focus on understanding the significance of the World Trade 
Organization’s (WTO) Agreement on Trade-related Aspects of Intellectual Property Rights 
(TRIPS), examine its main features and assess the ways in which it has altered the landscape of IP 
relations. In doing so the paper explores the key IP issues related to sustainable development, 
with emphasis on trends and outstanding questions in the international discourse. In this respect, 
the issues related to access to knowledge, access to health and the relationship between the 
international IP architecture and the protection of biodiversity and traditional knowledge (TK) has 
occupied much of the attention of policymakers. This paper accordingly centres its inquiry on 
these issues. We begin with a short introduction on the purpose and the main disciplines of 
intellectual property rights (IPRs). 
What are IPRs for? 
Intellectual property rights are conceived as a tool to reward innovators and creators for their 
contributions to society, for a statutory period of time. They are intended to provide the necessary 
incentives for the generation and dissemination of knowledge as well as to encourage the transfer 
of technology. They cover a wide range of interrelated disciplines, namely: 
• Patents, intended to protect and encourage new, inventive and industrially applicable 
inventions; 
• Utility models or petty patents, intended to protect the technical novelty of inventions 
that usually do not reach the legal standards required for patents; 
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• Undisclosed information, protecting secrets of commercial value (e.g. technical 
know-how, data of commercial value, test data); 
• Trademarks, protecting signs that distinguish goods or services of one undertaking 
from those of another undertaking; 
• Geographical indications (GIs), identifying a good as originating in a particular 
territory, or a region or locality, where a given quality, reputation or other 
characteristic of the good is essentially attributable to its geographic origin; 
• Copyrights, intended to protect original works of art, such as music, literature, 
cinema and other expressions of creativity; 
• Industrial designs, protecting the appearance of a product, the ornamental or aesthetic 
aspect of a useful object. They may consist of the shape, pattern, or colour of the 
object; 
• Integrated circuits (chips), intended to protect the layout design (or topographies) 
utilized in chips that are essential components in any digital equipment, and have 
been incorporated into a great variety of other industrial objets, ranging from machine 
tools to all kinds of household and consumer devices. 
The legal rules covering these disciplines tend to be complex and their economic, social 
and environmental impact is diverse and often difficult to measure. The extent to which these 
rules advance public policy objectives depends, to a great extent, on how international obligations 
are implemented, and this is particularly the case with respect to the attainment of sustainable 
development goals. One of the purposes of this paper is precisely to consider the main features of 
the international IP architecture and its relationship with sustainable development as it concerns 
access to knowledge, access to health and biodiversity. 
Organization of the study 
The study, organized around five chapters, deals mainly with: 
• Intellectual property and the international trading system including an analysis of the 
TRIPS Agreement and the importance of recent bilateral trade agreements including 
new standards of protection and the strengthening of enforcement measures. 
• Access to knowledge and its relationship with the present state of play in IP 
deliberations. Access and dissemination of knowledge relates to all IP disciplines but 
discussions have centred mainly in the areas of patents and copyrights. 
• The relationship between IP protection, particularly patents and undisclosed 
information, and access to medicines. 
• Genetic resources, biotechnological inventions and traditional knowledge and their 
interfaces with IPRs. 
• Finally, chapter 5 summarizes our main conclusions and findings particularly in the 
context of the Latin American and Caribbean region. 
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1. Intellectual property and the international 
trading system 
A. The agreement on trade related aspects of intellectual 
property rights 
The TRIPS Agreement constitutes a landmark in the evolution of IP law. Before TRIPS, countries 
could differentiate on the patentability of industrial or technological sectors and choose whether 
to protect processes and/or products. For example, by the time the General Agreement on Trade 
and Tariffs’s Uruguay Round negotiations started (1986), almost half of the patent laws 
throughout the world excluded pharmaceutical products from patent protection. Switzerland, a 
technologically advanced country, did not give full protection to pharmaceutical products until 
1976. Medicines and food-related products were among the sectors most frequently excluded 
from patent protection prior to TRIPS. 
In contrast to the dispersed nature of legal instruments dealing with IP, the TRIPS 
Agreement includes, in one single instrument, all the major IP disciplines and sets minimum 
standards of protection for them. These minimum standards are supplemented by the substantive 
provisions of, among others, the perennial IP treaties of the 19th century – the Paris and Berne 
Conventions – which are explicitly imported into TRIPS.  
Another major feature is the incorporation in the Agreement of disciplines related to the 
enforcement of rights. WTO Members are obliged not only to recognize and protect those rights 
but also to establish mechanisms that guarantee, through administrative, civil and criminal 
procedures, including border measures, the appropriate means for the domestic enforcement of 
those rights. Thus, the above-mentioned substantive provisions of the Paris and Berne 
Conventions are now subject to the enforcement provisions demanded by TRIPS. 
However, the most important consequence of TRIPS is the formal incorporation of IP 
into the international trading system. This means, inter alia, that the main foundations of the 
system –national treatment and most favoured nation treatment (MFN)– should apply to the IP 
relations between Members.  
The national treatment principle, already part of the classical IP conventions, 
acknowledges the principle of non-discrimination between nationals and foreigners, in the sense 
that WTO Members should accord foreign IP right holders a treatment similar to that accorded to 
their own nationals. But, compared for example to the Paris Convention of 1883, the national 
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treatment principle in TRIPS is expressed as “treatment no less favourable” than that accorded to 
own nationals, meaning that foreigners could be awarded better treatment than locals.  
The MFN principle is an important novelty in the evolution of the international IP 
architecture. MFN calls for non-discrimination by WTO Members between different foreigners. 
By this principle, which has very limited exceptions, nationals of different countries should not be 
treated differently over the protection of IP. One important consequence of this principle is that 
any advantage, favour, privilege or immunity granted by a WTO Member to a national of any 
other country – whether a WTO Member or not – is immediately and unconditionally extended to 
the nationals of all other WTO Members. This principle acquires particular relevance with the 
rising importance of bilateral trade agreements. 
Another major consequence of the full incorporation of IP into the international trading 
system is the application of the WTO’s Dispute Settlement Understanding (DSU) to the TRIPS 
Agreement (and also the substantive provisions of the Paris, Berne and Rome conventions and the 
Washington Treaty incorporated in TRIPS). The application of the DSU could justify measures of 
commercial retaliation, including cross-retaliation in the event of non-compliance with TRIPS 
obligations.1 This could be extended not only to violations of the Agreement but also to cases 
described in the WTO system as non-violation complaint situations.  
The TRIPS Agreement sets minimum standards for each type of IP covered by Part II of 
the Agreement, namely copyright and related rights, trademarks, geographical indications, 
industrial designs, patents, layout-designs of integrated circuits and undisclosed information.2 As 
observed above, in the pre-TRIPS landscape countries had the freedom to modulate the manner in 
which protection was fashioned for each of the IP disciplines. For example, they could exclude 
certain fields of technology from patent protection and determine the nature and duration of the 
rights granted. Under TRIPS, countries are obliged to accept at least these minimum standards, 
but may adopt more extensive protection.  
The Agreement at the same time provides for the freedom of implementation of its 
provisions, in the sense that Members are free to determine the appropriate method of 
incorporating its provisions into domestic law, within their own legal system and practice. This 
reflects the notion that the Agreement recognizes flexibilities and discretion in the 
implementation of its minimum standards. In this context, it is of note that the decision of the 
WTO panel in the US Section 110(5) of US Copyright Act (Home-style exemption) case refers to 
the argument made by the United States in its written submission concerning the freedom of 
implementation in Article 1.1 of TRIPS.3 In its submission, the US stated:  
“Article 1.1 of TRIPS also emphasizes flexibility, and provides that ‘Members shall be 
free to determine the appropriate method of implementing the provisions of this Agreement within 
their own legal system and practice.”4  
The acknowledgment that Article 1.1 “emphasizes flexibility” is significant. The question 
of flexibilities in the system has permeated the evolution of the TRIPS Agreement and has been 
the main bone of contention among governments. This reached a climax in discussions on the 
                                                     
1 
 See WTO case United States – Measures affecting the cross-border supply of gambling and betting services. Recourse by Antigua 
and Barbuda to Article 22.2 of the DSU. WT/DS285/22, p. 1, 22 June 2007, at http://www.wto.org/english/tratop_e/dispu_e/ 
cases_e/ds285_e.htm: “Pursuant to Article 22.2 of the WTO's Understanding on Rules and Procedures Governing the Settlement 
of Disputes (the “DSU”), Antigua and Barbuda requests authorization from the DSB to suspend the application to the United 
States of concessions and related obligations of Antigua and Barbuda under the General Agreement on Trade in Services (the 
“GATS”) and the Agreement on Trade-Related Aspects of Intellectual Property Rights (the “TRIPS”)”. 
2 
 Part II of TRIPS also deals with the control of anti-competitive practices in contractual licenses. 
3
  United States – Section 110(5) of the US Copyright Act, Report of the Panel, WT/DS160/R, 15 June 2000 (“U.S. – Copyright 
(Home-style Exemption)”), at para. 6.189 note 167. 
4 
 Ibid. Annex 2.1, First Written Submission of the United States, 26 October 1999, para. 21. 
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relationship between public health and IPRs that led to the adoption of the Doha Declaration on 
TRIPS and Public Health in 2001.5 Contention over this issue remains, as discussed further 
below. 
a) Exhaustion of rights and parallel trade 
The doctrine of exhaustion addresses the issue of when the IPR holder’s control over the 
distribution of a specific good ceases. This termination of control is critical to the functioning of 
any market economy because it permits the free transfer of goods. The basic idea is that once the 
right holder has been able to obtain an economic return from the first sale or placing a good on 
the market, the purchaser or transferee of the good is entitled to use and dispose of it without 
further restriction. Without an exhaustion doctrine, the original IPR holder would perpetually 
exercise control over the sale, transfer or use of a good or service embodying an IPR, and would 
control its economic life. From the standpoint of the international trading system, the focus of the 
exhaustion question is whether it operates on a national, regional or international basis.  
A country may choose to recognize that the exhaustion of an IPR occurs when a good is 
first sold or marketed anywhere outside its own borders (international exhaustion). If exhaustion 
occurs when a good or service is first sold or marketed outside a country, the IPR holder within 
the country may not oppose a given importation on the basis of its IPR. The importation of a good 
for which exhaustion of an IPR has occurred abroad is commonly referred to as “parallel 
importation”, and the goods subject to such trade are commonly referred to as “grey market 
goods”. On the other hand, countries may opt for a national exhaustion regime, whereby a right 
holder will be able to prevent an importation of a legitimate good if it was streamed into the 
channels of commerce outside the national territory. Countries that are members of a regional 
economic group might choose a regional exhaustion regime, as is the case of the members of the 
European Union (EU), whereby the rights will be exhausted if the goods are sold anywhere 
within that region. 
Exhaustion was one of the most difficult issues that arose during the negotiation of 
TRIPS (Gervais, 1998). The sole compromise was that each WTO Member would be entitled to 
adopt its own exhaustion policy and rules. This agreement was framed in Article 6, precluding 
anything in TRIPS from being used to address the exhaustion of rights in dispute settlement, 
subject to the TRIPS provisions on national and MFN treatment. This understanding was 
reaffirmed in the Doha Declaration on TRIPS and Public Health, which stated that in recognizing 
the flexibilities built into the Agreement, each WTO Member is free to establish its own regime 
on exhaustion of IPRs (UNCTAD-ICTSD Resource Book, 2005; Watal, 2001). 
b) The substantive minimum standards particularly with respect to 
patents 
As detailed above, a major feature of the TRIPS Agreement is the establishment of minimum 
standards of IP protection. This fundamental aspect of TRIPS differentiates it from previous IP 
conventions, in the sense that all WTO Members, without differentiation, are obliged to 
implement and comply with these minimum standards in their national legislation. The 
Agreement, however, recognizes, through transitional arrangements, some differentiation 
between categories of countries (i.e. developed countries, economies in transition to a free 
enterprise economic system, developing countries and least developed countries). The last of 
these transitional periods expired as of 1 January 2005 for all countries. However, subsequent 
                                                     
5
  See WTO document WT/MIN(01)/DEC/2, 20 November 2001 at http://www.wto.org/english/thewto_e/minist_e/min01_e/minde 
cl _trips_e.htm. 
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WTO decisions have waived the obligation of TRIPS implementation for the least developed 
countries (LDCs) until June 2013, in general, and, as a consequence of the Doha Declaration, 
until January 2016 for pharmaceutical products. 
Therefore, the Agreement signified a major cultural change in the international IP system. 
It raised levels of protection in almost all areas of IP to unprecedented levels, with respect to new 
rights, the scope of protected subject matter, terms of protection, enforcement and international 
dispute settlement procedures. However, TRIPS also left considerable room for manoeuvre by 
providing certain flexibilities.  
The flexibilities in TRIPS may take different forms. The Agreement, for example, does 
not define many of the terms in its provisions, allowing each WTO member to define the meaning 
of these terms to the extent that they may even help to define what the scope of a specific right 
will be or which matter will qualify for protection. Another kind of flexibility is given by the 
provisions in the TRIPS objectives (Article 7) and principles (Article 8), which are very useful for 
interpretation of the whole Agreement. As we have seen, an additional flexibility in the form of 
transitional implementation periods was given to developing and least-developed countries. 
Finally, the most common and probably the most important form of flexibility in TRIPS is that of 
limitations and exceptions to the rights granted. 
Among the substantive minimum standards for all categories of IP covered by the 
Agreement, probably the most far-reaching changes brought about by TRIPS concern patents and 
undisclosed information. In all the other areas covered by the Agreement, TRIPS fundamentally 
imported and expanded the main standards covered already in pre-existing World Intellectual 
Property Organization (WIPO)-administered treaties.  
With respect to patent protection, the Agreement includes a number of important 
obligations for Member countries that limit the legislative freedom they enjoyed prior to TRIPS. 
(i) Patents available in all fields of technology 
According to TRIPS, patents shall be available for any inventions, whether products or processes, 
in all fields of technology, provided that they are new, involve an inventive step and are capable 
of industrial application.6 The Agreement also underlines that patents shall be available and 
patent rights exercised without discrimination as to the place of invention, the field of technology 
and whether products are imported or locally produced. 
Whilst stating this principle of non-discrimination with respect to the patentability of 
inventions in all fields of technology, the Agreement leaves WTO Members the flexibility, within 
the broad parameters of the provisions of TRIPS, to characterize what an invention is for the 
purpose of granting a patent. This is, in a way, another manifestation of the flexibilities referred 
to above. There have been efforts to further harmonize international standards in this area, such as 
the negotiations in WIPO on a Substantive Patent Law Treaty (SPLT) to which we refer below. 
An example of the use of this flexibility is the Indian Patent Law of 2005, which defines or 
excludes a number of acts from the notion of inventions.7 
                                                     
6
 For these purposes the terms “inventive step” and “capable of industrial application” may be deemed by a Member to be 
synonymous with the terms “non-obvious” and “useful” respectively. 
7
  See Amir (2007). The relevant section of the Indian law provides: Section 3: The following are not inventions within the meaning 
of this Act, (d): “the mere discovery of a new form of a known substance which does not result in the enhancement of the known 
efficacy of that substance or the mere discovery of any new property or new use for a known substance or of the mere use of a 
known process, machine or apparatus unless such known process results in a new product or employs at least one new reactant 
“Explanation: For the purpose of this clause salts, esters, polymorphs, pure form, particle size, isomers, mixtures of isomers, 
complexes, combinations and other derivatives of known substance shall be considered to be the same substance unless they 
differ significantly in properties with regard to efficacy.”  
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The TRIPS Agreement, at the same time, establishes general rules on the type of 
exclusions countries can make to the patentability of inventions:  
“Members may exclude from patentability inventions, the prevention within their 
territory of the commercial exploitation of which is necessary to protect ordre public or morality, 
including to protect human, animal or plant life or health or to avoid serious prejudice to the 
environment, provided that such exclusion is not made merely because the exploitation is 
prohibited by their law. (Article 27.2)  
Members may also exclude from patentability: diagnostic, therapeutic and surgical 
methods for the treatment of humans or animals (Article 27.3(a))”. 
Notably, from a sustainable development perspective, the reference made here to “the 
environment” is the sole mention of this concept in the Agreement. There is no clear indication in 
the legislative history of the Agreement as to how it was incorporated in the text. No reference to 
the “environment” was made in the earlier negotiating texts until its incorporation in the Dunkel 
draft (1991) that was the basis of the final agreed text. National laws have incorporated this type 
of exclusion to patentability in the implementation of TRIPS.8  
A subsequent standard regarding exclusions from patentability is the provision in Article 
27.3(b) dealing with biotechnological inventions, including genetic resources, and plant variety 
protection. We deal with this matter in Chapter 4. 
In brief, Article 27 of TRIPS adds to the argument made above that TRIPS radically 
departed from the system prevailing prior to 1995, where countries could exclude industrial 
sectors that, for social or economic considerations, were not considered fit for patentability. That 
was the common practice with respect to products related to medicines and food. 
(ii) Rights and exceptions 
Another major feature of the Agreement is that it provides for an exhaustive description of the 
exclusive rights conferred by a patent. These include the right to prevent third parties, who do not 
have the right holder’s consent, from the acts of: making, using, offering for sale, selling, or 
importing for these purposes, the product (in the case of a product patent) or the product obtained 
directly by that process (in the case of a process patent). The Agreement adds that the term of 
protection shall not end before the expiration of a period of 20 years counted from the filing date. 
The national practices prior to TRIPS varied with some countries recognizing a 20 year patent 
term and others, such as India, differentiating the term according to sectors. We will see below 
that in recent free trade agreements (FTAs) the 20 year term may be extended further to take into 
account delays in the administrative grant of a patent or delays resulting from the marketing 
approval process of a pharmaceutical product or an agrochemical product. 
The exclusive rights conferred to the patent holder are not unqualified. Under most patent 
laws, such rights may not be exercised with regard to certain acts considered legitimate, for 
example in relation to non-commercial acts (e.g. private use or scientific research) or for 
regulatory purposes (e.g. “Bolar exception”). This means that under certain specified 
circumstances, there may be exceptions to the exclusive rights. In general, the Agreement limits 
the establishment of such exceptions to those that “do not unreasonably conflict with a normal 
                                                                                                                                                              
 Source: Indian Patent Office at http://www.patentoffice.nic.in/ipr/patent/patents.htm. The Swiss firm Novartis has brought a 
major case of TRIPS compliance against the Indian government challenging the use of this flexibility. See http://www.ip-
watch.org/weblog/index.php?p=657&res=1280_ff. 
8
  For instance, see Article 10(IX) and Article 18 of Brazil’s Industrial Property Law - Law Nº 9.279, of May 14, 1996 at 
http://www.sice.oas.org/int_prop/nat_leg/Brazil/ENG/L9279eA.asp#nonpat; and Article 37 of Chile’s Industrial Property Law – 
Ley 19.039 at http://www.bcn.cl/leyes/pdf/actualizado/250708.pdf. 
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exploitation of the patent and do not unreasonably prejudice the legitimate interests of the patent 
owner, taking account of the legitimate interests of third parties” (Article 30).  
Article 30 of TRIPS was the subject of close examination in the WTO case Canada 
Patent Protection of Pharmaceutical Products.9 The case was brought against Canada by the EU, 
questioning the regulatory review exception (“Bolar exception”) provided for in Canadian patent 
law. The Bolar exception in Canada’s case recognized that acts by a third party (generic industry) 
related to the development and submission of information required under the law regulating the 
manufacture, use or sale of any product, was not an infringement of the patent. The exception, 
under Canadian law, was also extended to the stockpiling of products intended for sale 
immediately after the expiration of the patent. The WTO panel, effectively constructing the 
boundaries of the Article 30 exceptions to patents, found that the stockpiling provision in the 
Canadian law was inconsistent with international law, but also stated that the exception contained 
in Canadian law related to testing was “limited” within the meaning of Article 30:  
“The exception is ‘limited’ because of the narrow scope of its curtailment of Article 28.1 
rights. As long as the exception is confined to conduct needed to comply with the requirements of 
the regulatory approval process, the extent of the acts unauthorized by the right holder that are 
permitted by it will be small and narrowly bounded. Even though regulatory approval processes 
may require substantial amounts of test production to demonstrate reliable manufacturing, the 
patent owner’s rights themselves are not impaired any further by the size of such production 
runs, as long as they are solely for regulatory purposes and no commercial use is made of 
resulting final products”.10  
In brief, the Agreement defines the scope of the rights covered by the patent. Those rights 
could be limited under the conditions set in Article 30 of TRIPS and also by the system of 
compulsory licensing as follows. 
(iii) Compulsory licensing 
An important limitation to the exclusive rights of the patent holder relates to the authorization by 
governments of non-voluntary uses to third parties (commonly known as compulsory licensing). 
In this context, the Agreement sets up conditions or modalities in case countries allow for other 
use of the subject matter of a patent without the authorization of the right holder, including use by 
the government or third parties authorized by the government. The Agreement does not provide 
for a straightforward recognition of these uses, but acknowledges that Members allowing such 
licenses in their domestic legislation should comply with a number of conditions. Compulsory 
licenses are not a novelty in the IP system. They were introduced to the Paris Convention in the 
Review Conference of 1925. However, a new feature in TRIPS is the specific conditions that 
govern the granting of a compulsory license. 
The main conditions set in TRIPS are: 
• The consideration on a case-by-case basis of the individual merits of the request; 
• The need for the proposed user to have negotiated previously with the right holder on 
reasonable commercial terms and conditions for a license to use the invention. This 
requirement may be waived in the case of a national emergency or other 
circumstances of extreme urgency or in cases of public non-commercial use; 
                                                     
9
  See WTO Case ref. WT/DS114/R, 17 March 2000. 
10
  Ibid, para. 7.45 
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• That the scope and duration of such use shall be limited to the purpose for which it 
was authorized; 
• That such use shall be non-exclusive; 
• That any such use shall be authorized predominantly for the supply of the domestic 
market of the Member authorizing such use; 
• That authorization for such use shall be terminated if and when the circumstances 
that led to it cease to exist and are unlikely to recur; 
• That the right holder shall be paid adequate remuneration in the circumstances of 
each case, taking into account the economic value of the authorization; 
• That the legal validity of any decision relating to the authorization of such use and to 
any decision relating to the remuneration shall be subject to judicial review or other 
independent review by a distinct higher authority in that Member.  
An interesting practical example of the compulsory licensing system related to 
biotechnological inventions is provided by the European Directive (98/44/EC) to which we refer 
in subsequent sections of this paper. The Directive provides for compulsory licensing to facilitate 
the acquisition or exploitation of a plant variety without infringing a prior patent and, conversely, 
to facilitate the exploitation of a patent without infringing a prior plant variety right. In these 
circumstances, the breeder or the holder of a patent concerning a biotechnological invention may 
apply for a compulsory license, for a non-exclusive use of the patent or of the plant variety. In 
both cases, the Directive provides for a cross-license to the other party.  
We return to compulsory licensing in chapter 3. 
B. The bilateral trade agreements 
A major new development in the IP landscape has been the emergence of a new 
generation of bilateral free trade agreements that include comprehensive and robust 
chapters covering IP disciplines. While the main aim of FTAs is increased market access, 
these agreements contain a number of trade-related regulations, including, besides IPRs, 
rules on investment, services and government procurement. These agreements adopt 
different names. For the sake of convenience we refer to these bilateral, trilateral or 
regional trade agreements collectively as FTAs. The IP obligations in these agreements 
are notable for expanding the minimum standards of protection and enforcement beyond 
that which is laid out in the TRIPS Agreement. The main driving force behind this trend 
has been the US. But the EU and the European Free Trade Association (EFTA) have also 
been active in negotiating trade agreements with different emphases on IP issues. The EU 
has recently become more active in this area by launching negotiations on Economic 
Partnership Agreements (EPAs) – that include IP issues – with six regional groupings of 
the African, Caribbean and Pacific (ACP) states (Santa Cruz, 2007). Table 1 lists the 
various FTAs negotiated or currently under negotiation that involve Latin American and 
Caribbean countries. 
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TABLE 1 
FREE TRADE AGREEMENTS INVOLVING LATIN AMERICAN AND CARIBBEAN 
COUNTRIESa 
Country Negotiated Under Negotiation 
US with - 1992: NAFTA (Canada and Mexico) 
- 2003: Chile  
- 2005: (CAFTA-DR) Central America and Dominican 
Republic  
- 2006: Peru; Colombia  
-2007: Panama  
- Free Trade Agreement 
of the Americas (FTAA); 
Ecuador;  
 
EU with - 1997: Mexico  
-2000: ACP Countries – Cotonou Agreement 
- 2002: Chile 
- Andean Communityb; 
Central America; 
Mercosurc 
- ACP countries  
EFTAd with - 2000: Mexico  
- 2003: Chile  
 
Canada with - 1992: NAFTA (Mexico and US) 
- 1996: Chile 
- 2001: Costa Rica 
 
Republic of Korea with -2005: Chile - Canada 
Japan with - 2005: Mexico  
- 2007: Chile-  
 
Taiwan with - 2005: Panama  
Sources: www.ustr.gov; http://ec.europa.eu/comm/trade/issues/bilateral/index_en.htm; http://secretariat.efta.int; 
www.bilaterals.org. 
a
 Dates refer in general to the year that the respective agreement was signed 
b
 Bolivia, Colombia, Ecuador, Peru  
c
 Argentina, Brazil, Paraguay, Uruguay 
d
 Norway, Lichtenstein, Iceland, Switzerland 
 
While most developing countries are still struggling to implement the minimum standards 
detailed in the TRIPS Agreement, these FTAs pose important challenges. Civil society groups 
have expressed concerns that the TRIPS-plus provisions contained in these agreements raise 
significant obstacles, particularly with respect to the use of flexibilities in the implementation of 
these agreements (Oxfam, 2007). It should be noted that these TRIPS-plus provisions do not 
contravene the Agreement since they legitimately build on its minimum standards. We return to 
the relevance and implications of the FTAs in IP policy making in the subsequent chapters of this 
paper. 
The developments outlined above are reinforced by the clear determination of more 
advanced countries to move forward their strategies to strengthen the monitoring of the ways and 
methods used by countries, particularly developing ones, to implement their commitments and 
enforce IPRs at the domestic level. The US and the EU have stated this in plain and 
straightforward language, expressing their intent to bring these matters under the consideration of 
the WTO Council for TRIPS, whilst persisting in their unilateral measures to identify and 
publicize specific countries that in their view are not fully compliant with their international 
obligations (Roffe, 2007). The importance of this angle of the debate on IP issues was highlighted 
in the Declaration of the G8 Summit held in Heiligendamm, Germany on 7 June 2007.11 
                                                     
11 
 Available at http://www.g-8.de/Webs/G8/EN/G8Summit/SummitDocuments/summit-documents.html. 
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2. Access to knowledge 
Historically, IP systems have been constructed around the notion that there is a need for state 
intervention in securing and rewarding innovators and creators for their contributions to society 
and for the knowledge that is being created. Society prospers, culturally and economically, 
through innovation and the creation of new ideas. This concept is well expressed in the 
Constitution of the United States:  
“The Congress shall have the power to promote the Progress of Science and useful Arts, 
by securing for limited Times to Authors and Inventors the exclusive Right to their respective 
Writings and Discoveries”.12  
In attempting to survey some of the major issues around access to knowledge, this 
chapter begins with some general considerations as to the role and rationale of the IP system. It 
follows with observations on the relationship between foreign direct investment (FDI), transfer of 
technology and IPRs. It deals next with what we characterize as the checks and balances of the 
system to ensure that IP protection reinforces its contribution to knowledge dissemination. The 
chapter also considers issues that have arisen in recent FTAs that might affect access to 
knowledge, particularly with respect to copyright. Finally, it reviews some positive developments 
in WIPO around the notion of a development agenda and its relation with deliberations on access 
to knowledge. 
A. Access to knowledge at the centre of the IP system 
It is implicit that the exclusive rights granted to authors and innovators should also encourage 
future authors and innovators to use those contributions to further technological and cultural 
progress. Thus, access to knowledge is at the centre of the IP system. This was well captured in 
the TRIPS Agreement under its objectives and principles:  
“Intellectual property rights should contribute to the promotion of technological 
innovation and to the transfer and dissemination of technology, to the mutual advantage of 
                                                     
12 
 US Constitution, Article 1, Section 8, Clause 8. 
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producers and users of technological knowledge and in a manner conducive to social and 
economic welfare, and to a balance of rights and obligations”.13  
According, then, to the TRIPS Agreement, the changes that have taken place in recent 
years should contribute to the dissemination of knowledge and to improved forms of transfer of 
technology. In view of their recent implementation, it could be too early to assess this aspect of 
the impact of TRIPS and TRIPS-plus treaties. For most developing countries TRIPS entered into 
force in January 2000, since in a number of cases legislative reforms, particularly in Latin 
America, preceded that date. Furthermore, FTAs are a new vintage and the implementation 
process has only recently started; some countries have signed but not yet implemented FTAs, 
such as Costa Rica, which at the time of writing has not yet ratified the Dominican Republic and 
Central America Free Trade Agreement (DR-CAFTA or CAFTA-DR) with the US. But, even in 
this case, Costa Rica has already amended its IP regime in line with TRIPS compliance.  
Access and dissemination of knowledge then, could be considered as the quid pro quo of 
granting monopoly rights. However, some have raised concerns as to whether the bargain 
between society at large (benefiting from the knowledge produced and disseminated by IP) and 
the right holders (benefiting from their time-limited monopoly) is indeed being fulfilled. 
Although, the issue of access to knowledge is present in all areas of IP, there seems to be a more 
articulated debate in the area of copyright. But a unifying feature of all the arguments in favour of 
access to knowledge is the fact that overreaching rights could have adverse consequences in 
different areas of society, thus obstructing social development. More recently, civil society 
groups, via the A2K (Access to Knowledge) movement, have related access to knowledge to 
principles of justice, freedom and economic development.14  
Certain societal actors are highly dependent on access to knowledge goods. Hence, the 
activities of, among others, researchers, libraries, educational institutions, people with disabilities, 
publishers and media rely heavily on a robust public domain and on clear exceptions and 
limitations to rights. Overreaching rights and even abuses by right holders may defeat the whole 
purpose of IP of providing incentives for creativity and innovation to further the progress of 
society, by impeding the use of legitimate exceptions and limitations and delaying the entry of 
works and inventions into the public domain. Licenses and contracts are often used to restrict the 
use of exceptions and limitations, and, as we will see below, digital locks (known as 
technological protection measures or TPMs), although useful to protect works, may also have 
unintended consequences for the use of legitimate exceptions and limitations and works in the 
public domain.  
For instance, the existing IP system, including the TRIPS Agreement, is based on the 
assumption that the given state will recognize certain rights for authors and inventors for a certain 
period of time, after which the works and inventions will fall into the public domain. Some have 
raised concerns as to whether the terms of protection are too long, and, moreover, whether 
subsequent extensions of the terms of protection, either unilaterally or through trade agreements, 
beyond the minimum required by TRIPS may have an adverse effect on the enrichment of the 
public domain.  
In addition to concerns over such extension per se, other problems relate to the implicit 
encouragement in the TRIPS Agreement of upward harmonization of the terms of protection of 
copyright, as this issue is subject to reciprocity15 instead of the general rule of national treatment. 
                                                     
13
  TRIPS, Article 7. 
14
  “The Access to Knowledge movement (also known as A2K) is a loose collection of civil society groups, governments, and 
individuals converging on the idea that access to knowledge should be linked to fundamental principles of justice, freedom, and 
economic development”. See http://en.wikipedia.org/wiki/Access_to_Knowledge_movement. 
15
  Berne, Article 7.8. 
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In other words, the Agreement provides that the “term shall be governed by the legislation of the 
country where protection is claimed; however, unless the legislation of that country provides 
otherwise, the term shall not exceed the term fixed in the country of origin of the work” 16. 
Normally, as in mostly every other TRIPS (and Berne) provision, a right holder would 
unconditionally get the same treatment as the nationals of the country where the protection is 
sought.17  
Finally, the extension of the terms of copyright cover works that are already copyrighted, 
contradicting the argument that copyrights are granted to encourage creativity.18 As we will see, 
in the case of patents there is already a trend of extending the terms of protection when there have 
been delays in the granting of the patent, and also when there have been delays in the process of 
granting marketing approval for pharmaceutical products.  
Additionally, the system is based on the premise that certain things may never be 
protected because the burden on society would be too heavy. The contours of protection are 
defined by the scope of protection, protected subject matter and rights granted. Therefore, 
according to TRIPS (the scope of) copyright “shall extend to expressions and not to ideas, 
procedures, methods of operation or mathematical concepts as such”.19 In the case of patents, 
certain requirements of novelty, inventive step, and industrial applicability must be fulfilled in 
order to get the statutory 20 years of protection. In the case of trademarks, certain words may 
never be trademarked (generic terms), while descriptive terms may not be protected, unless a 
secondary meaning can be proven. Otherwise, the trademark holder would impede its competitors 
to use the only term to designate their products. In the case of the protection of undisclosed 
information, WTO Members have decided to protect certain investments on pharmaceutical and 
agricultural chemical products, but only if a “considerable effort” has been made.  
Regarding patents specifically, there are cases where the patent holder does not 
sufficiently disclose the invention in the patent application (i.e. it cannot be carried out by a 
person skilled in the art), effectively not allowing others to put the invention into practice and to 
benefit from that knowledge.20 There are also cases where patent holders accumulate several 20 
year terms of protection for different aspects of a single product. This practice, known as 
“evergreening”, is often seen in the pharmaceutical industry. 
Besides some criticism for too-broad and overreaching IPRs, the more positive view of 
the IP system from the perspective of access to knowledge is that IPRs may contribute, or may be 
used, in a more pro-competitive manner and with the idea that sharing knowledge will lead to 
more creation and innovation. The open source movement, Creative Commons licenses, 
collaborative projects such as Wikipedia,21 and the use of compulsory licenses are manifestations 
of this idea. Its most extreme expression could be the copyleft movement, by which authors give 
up their copyright so that their works fall automatically into the public domain.22 
                                                     
16 
 Indeed, this was one of the major arguments made in favour of extending the terms of copyrights in the US. See Senate Report 
104-315, p.3 at http://frwebgate.access.gpo.gov/cgi-bin/getdoc.cgi?dbname=104_cong_reports&docid=f:sr315.104.pdf. 
17
  Among the reasons given in the US to increase the term of protection from life of the author plus 50 years to life of the author plus 70 years, 
was the fact that some European Union countries had already extended the term to life of the author plus 70 years without automatically 
extending them to foreigners. Therefore, the effect of increasing the term in the US would be that US authors would gain the same protection as 
European author in Europe. See http://thomas.loc.gov/cgibin/cpquery/R?cp104:FLD010:@1(sr315). 
18
  Berne, Article 18.4. 
19
  TRIPS, Article 9.2. 
20  See European Patent Office, Guidelines for Patent Examination, Rules 4.9. and 4.11 at http://legis.obi.gr/ESPACEDVD/legal_texts/ 
gui_lines/e/c_ii_4_9.htm. 
21
  http://www.wikipedia.org/. 
22 
 http://www.gnu.org/copyleft/. 
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B. Measuring access to knowledge through patent applications, 
FDI and licensing of technology 
One salient feature of recent IP developments is the extraordinary rise in the number of patent 
applications throughout the world. According to WIPO statistics,23 between 2001 and 2004 patent 
applications averaged 1.5 million per year, compared to 1 million in 1987, the year in which the 
Uruguay Round was launched. However, more than 80% of the applications are made in Japan, 
the US, the Republic of Korea, China, the European Patent Office and Germany. Brazil, the 
largest recipient of patent applications in Latin America and the Caribbean, had fewer than 7000 
applications in 2004. Latin American and the Caribbean countries receive, altogether, around 5% 
of the patent applications made in the world. It should be stressed that most of these applications 
are from non-residents, mostly from the US, which represents one third of total non-resident 
applications. In terms of patents actually granted, the region represents fewer than 2% of the 
patents granted annually around the world. At the same time, the number of applications made by 
Latin American and Caribbean nationals in the US Patent Office is less than 1% of the total. 
Thus, in global terms the region is a marginal player with respect to patent applications, both as 
recipient and as applicant in foreign countries. 
With all the necessary caveats, the size of these figures could be indicative of the 
dissemination of knowledge factor, bearing in mind that patents might contain important 
technical information than could be used to understand the state of the art in particular fields and 
to produce new innovations based on the technical information contained in patent applications. 
A factor contributing to the rise of patent applications, including in the Latin American 
and Caribbean regions, relates to the strengthening of IP regimes as evidenced since the launch of 
the Uruguay Round. This should in theory be a contributing factor to improving the dissemination 
of knowledge and the transfer of technology. However, this requires further examination.  
Relating to the access of knowledge factor, an argument often made in favour of 
advanced and strengthened IP regimes is that they would improve the foreign investment climate 
and thus attract more and quality FDI, contributing further to the transfer of advanced 
technologies generally controlled by transnational corporations. In the case of Latin America, 
according to the United Nations Conference on Trade and Development (UNCTAD): 
Following four years of continuous decline, FDI flows to Latin America and the 
Caribbean registered a significant upsurge in 2004, reaching $68 billion – 44% above the level 
attained in 2003… Brazil and Mexico were the largest recipients…Together with Chile and 
Argentina they accounted for two-thirds of all FDI flows into the region in 2004.” 24  
Figures for 2005 confirm the steadiness of FDI flows and their concentration in a few 
countries. It is interesting to note that the countries of origin of those flows are mainly the US, 
France, the Netherlands and Spain. With the exception of Spain, the others countries are the main 
origin of patenting by non-residents in the region.  
The available literature is ambivalent on the role IP plays as a factor in FDI. There is 
some consensus that IP protection plays a positive role in the context of a broader package of 
policies and incentives. Isolated from other policy instruments, its role is not so obvious. It is 
often mentioned that on paper a number of African countries provide a high level of IP 
protection, although their enforcement mechanisms might be weak. Africa in general does not 
receive significant flows of FDI or transfer of technology, which reinforces the view that 
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  http://www.wipo.int/ipstats/en/. 
24 
 UNCTAD (2005) World Investment Report. 
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strengthening IP is not sufficient for these purposes. It is commonly observed that flows of FDI 
are not necessarily targeted to countries with strong IP systems (China might be a case in point), 
but that there are other factors that determine the quantity and quality of such flows. FDI flows 
depend on factors such as costs, size of the market, transaction costs and other factors, such as the 
local situation in the place of the investment.  
The literature also observes that IP protection might be important as a factor for FDI in 
specific industries which are more sensitive to IP protection and where imitation and copying is 
less complex, as in the pharmaceutical and chemical sector. Moreover, the IP harmonization 
process could also make FDI less attractive compared to licensing that could become a more 
efficient and secure scheme for the transfer of technology. At the same time, it is also observed 
that the convergence of IP systems through this harmonization process, initiated by TRIPS, could 
entail that IP as a factor for the localization of FDI and for the transfer of technology could 
become less relevant. This geographical expansion of IP would allow the transnational firm to 
serve a particular market via exports and without necessarily a local presence (Maskus, 2004).  
In general, scholars are of the view that these issues are still uncharted waters:  
“Economic analysis has come up short of providing either theoretical or empirical 
grounds for assessing the overall effect of intellectual property law on economic welfare… 
[E]xpanding intellectual property rights can actually reduce the amount of new intellectual 
property that is created by raising the creators’ input costs, since a major input into new 
intellectual property is such existing property. This is true in both the patent and copyright areas 
and makes us sceptical about proposals to enlarge intellectual property rights in those areas. Any 
further enlargement would increase access and transaction costs and could at the same time 
weaken rather than strengthen the incentives to create new intellectual property” (Landes & 
Posner, 2003).  
The strengthening of IP should have contributed to transfer of technology via licensing 
agreements, as suggested above. One way of measuring this could be the nature of the payments 
made for concepts such as royalties for patents, trademarks, industrial know-how and copyright. 
Based on data provided by the US Bureau of Economic Analysis, an important rise can be 
perceived in the payments made to the US in recent years. Since 1986, the year the Uruguay 
Round was launched, those payments have risen six-fold (CAF, 2005). 
This increase in royalty payments could have positive and negative interpretations from 
the viewpoint of access to knowledge and the transfer of technology. On the positive side, it 
might reflect a tendency to an expansion in the transfer of technology to the region in the sense 
that more payments could mean new technology transactions, influenced by the changes made 
recently in the IP regimens of the region. However, this phenomenon has occurred mainly within 
firms, namely between parent and subsidiaries and less between independent firms.25 The 
counterargument here could be that the strengthening of IP rights has made technology more 
expensive and difficult to access. This would reaffirm the argument made by some that the TRIPS 
Agreement and the TRIPS-Plus process would result in a net transfer of resources from 
developing countries to the technologically most advanced countries, such as Germany, the US 
and France (UNCTAD-ICTSD, 2003). 
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  See Branstetter. 
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C. Checks and balances: flexibilities, exceptions and 
limitations 
Access to knowledge could also be tested by the necessary checks and balances that an IP 
system should have. In this respect, a common form of imitating and upgrading 
technological skills has been reverse engineering. Many firms and countries employed 
this technique to industrialize. In the pre-TRIPS era, when the IP system was laxer and 
more flexible, reverse engineering was easier to achieve. With stronger IP regimes and 
better modes of enforcement, reverse engineering has become more difficult but not 
unattainable under the aegis of the new international IP architecture. 
The expansion of the IP system to new frontiers, covering new subject matter, 
could also impinge upon the public domain, i.e. technologies or knowledge not covered 
by IPRs or whose protection has expired and which is therefore available to interested 
parties, thus making access to knowledge more difficult.  
Linked to this question is the whole issue of flexibilities in the implementation of 
national IP regimes. The starting point here is that TRIPS –and even more so the new 
generation of FTAs– has limited countries’ ability to exercise such flexibilities. 
Flexibilities are mainly expressed in the form of exceptions or limitations that can be 
formulated in national laws. Exceptions and limitations can take a number of forms. For 
example, in the case of copyright, limitations and exceptions could include those related 
to the promotion of competition in a given technology to permit interoperability, so that 
two or more systems can interact (e.g. a computer functioning with software from other 
companies) or to the efforts of educational institutions to utilize the most effective 
technological means to communicate with and train students (Okediji, 2004). In the case 
of patents (as well as in all categories of IP), typical exceptions might include the 
treatment of the exhaustion of rights (see discussion in Chapter 1 above) and the 
regulatory exception in the case of pharmaceutical products to allow for the marketing 
approval of generics before the expiration of a patent, in order that it can reach the 
market without delay upon expiration of the patent. Another exception commonly used, 
particularly in developed countries, relates to experimental and scientific use (Garrison, 
2006). 
The TRIPS Agreement sets general parameters as to the use of exceptions. For 
instance, Article 30 states that: 
“Members may provide limited exceptions to the exclusive rights conferred by a 
patent, provided that such exceptions do not unreasonably conflict with a normal 
exploitation of the patent and do not unreasonably prejudice the legitimate interests of 
the patent owner, taking account of the legitimate interests of third parties”. 
As we have seen a common limitation to the exclusive rights conferred by a patent 
is the possibility of using the patent without the patent holder’s authorization in certain 
events and under conditions established in national regimes. These are commonly known 
as compulsory licenses permitted under TRIPS, a subject to which we return in the next 
chapter. 
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D. The FTAs and the issue of circumvention of technological  
measures: their potential impacts on access to knowledge 
As noted, the FTAs deepen the process of harmonization started in TRIPS and therefore limit 
further the use of flexibilities. This is particularly relevant in the field of copyright where the 
FTAs provide for strict rules against the circumvention of technological protection measures 
(TPMs) used by authors, performers and the producers of phonograms to protect their works, 
performances and phonograms protected by copyright and related rights. 
The provisions on TPMs go beyond the WIPO Internet treaties of 1996 (the WIPO 
Copyright Treaty and the WIPO Performances and Phonograms Treaty), which state only that 
parties “shall provide adequate legal protection and legal remedies” against the circumvention of 
TPMs, leaving it to each Party to decide the way in which it will implement the provisions and 
whether it will apply civil and/or criminal sanctions to infringers. 
The FTAs, in general, contain detailed rules aimed at providing adequate legal protection 
and effective legal remedies to fight against the circumvention of effective technological 
measures.26 In a key provision of the CAFTA-DR Agreement, Parties are committed to provide 
that any person who: 
“(i) circumvents without authority any effective technological measure that controls 
access to a protected work, performance, phonogram or other subject matter; 
(ii) manufactures, imports, distributes, offers to the public, provides, or otherwise traffic 
in devices, products, or components, or offers to the public or provides services, that: 
a) are promoted, advertised, or marketed for the purpose of circumvention of any 
effective technological measure; or 
b) have only a limited commercially significant purpose or use other than to 
circumvent any effective technological measure; or 
c) are primarily designed, produced, or performed for the purpose of enabling or 
facilitating the circumvention of any effective technological measure, shall be 
liable… Each Party shall provide for criminal procedures and penalties to be 
applied when any person, other than a non-profit library, archive, educational 
institution, or public non-commercial broadcasting entity, is found to have 
engaged wilfully and for purposes of commercial advantage or private financial 
gain in any of the foregoing activities (Article 15.5.7 (a)).” 
The terminology of the TPM provisions found in the FTAs draw from the controversial 
US Digital Millennium Copyright Act (DMCA),27 which was “nominally intended to bring US 
law into compliance with the 1996 WIPO Treaties on copyright and the Internet, but in fact went 
well beyond what those treaties required”( Lemley et al, 2000). 
These strong provisions make it a civil and criminal offence to tamper with embedded 
anti-piracy measures that control access to works and phonograms. They also provide for civil 
liability, and, when done wilfully and for prohibited commercial purposes, criminal liability for 
the manufacture, import, distribution, sale or rental of devices, products or components that serve 
                                                     
26  
“Effective technological measure means any technology, device, or component that, in the normal course of its operation, controls 
access to a work, performance, phonogram, or any other protected material, or that protects any copyright or any rights related to 
copyright, and cannot, in the usual case, be circumvented accidentally.” Article 17.7.5 (f), FTA US-Chile 
27 
 U.S.C. Title 17 § 1201 
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the purpose of circumventing TPMs that control access and the exclusive rights in a work or 
phonogram.28 
Critics of the TPM provisions of the DMCA argue that they impede lawful uses of works, 
such as making a copy of a music CD to listen to it on a computer, making a backup copy of a 
computer program or copying small parts of a DVD movie for the purpose of teaching or 
criticism. TPMs have also been used to bar the manufacture of competing products, to suppress 
speech, to limit the first sale doctrine and to fragment markets, such as through regional codes on 
DVDs29. Moreover, the use of TPMs restricts access to works that have already fallen into the 
public domain. The incidence of these provisions in FTAs has been criticized precisely for 
limiting access to information technology:  
…a series of bilateral trade agreements negotiated by the USA have included DMCA like 
provisions, and thus made these inordinately high standards a de facto model for global 
implementation of the WCT [WIPO Copyright Treaty]. The combined effect of private law 
mechanisms such as torts and contract law, and public law regulation through copyright and 
other specialized regimes like the DMCA, will lead inevitably to increased difficulty in access to 
content. In a situation where access to hardware is already an important hindrance to developing 
countries, adding another layer of impediments, and inevitably raising costs, is problematic for 
the interests of developing countries in utilizing information technology (Okedji, 2004). 
Only very limited exemptions are permitted to the FTA provisions aimed at providing 
adequate legal protection and effective legal remedies to fight against circumvention of effective 
technological measures, an example being for reverse engineering to achieve interoperability 
between computer programs. 
E. Access to knowledge and WIPO 
Recent developments in WIPO both directly and indirectly relate to access to knowledge. For 
instance, in the context of the Standing Committee on Copyrights and Related Rights (SCCR), 
Chile submitted a proposal in November 2004 to include in the deliberations of the Committee 
exceptions and limitations for libraries, educational purposes and disabled persons.30 The 
proposal has gained support and has led the WIPO secretariat to prepare studies on “Limitations 
and Exceptions for the Visually Impaired”31 and on exceptions and limitations for libraries.  
In the context of discussions on a Development Agenda for WIPO (see Box 1), member 
states have agreed on several recommendations dealing in one way or another with the broad 
issue of access to knowledge. Most importantly in June 2007, members agreed to “initiate 
discussions on how, within WIPO’s mandate, to further facilitate access to knowledge and 
technology for developing countries and LDCs to foster creativity and innovation and to 
strengthen such existing activities within WIPO”.32  
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 “The DMCA was a bit of law intended to back up the protection of [this] code designed to protect copyrighted material. It was, 
we could say, legal code intended to buttress software code which itself was intended to support the legal code of copyright”. 
Lessig (2004). 
29 
 Electronic Frontier Foundation, Unintended Consequences: Seven Years under the DMCA April, 2006. See 
http://www.eff.org/IP/ DMCA/?f=unintended_consequences.html#Section5. 
30 
 See WIPO documents SCCR/12/3 at http://www.wipo.int/meetings/en/doc_details.jsp?doc_id=34747 and SCCR/13/5 at http: 
//www.wipo.int/meetings/en/doc_details.jsp?doc_id=53350. 
31 
 See WIPO document SCCR/15/7 at http://www.wipo.int/meetings/en/doc_details.jsp?doc_id=75696. 
32 
 See http://www.wipo.int/ip-development/en/agenda/pcda07_session4.html. 
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BOX 1 
THE WIPO DEVELOPMENT AGENDA 
The ‘Development Agenda’ proposed in 2004 by Argentina and Brazil aims to make development a crucial 
element of all negotiations taking place in WIPO and in policy making on intellectual property protection in 
general. According to the proponents, known as ‘the Friends of Development’ (FoD) (Argentina, Bolivia, 
Brazil, Cuba, Ecuador, Egypt, Islamic Republic of Iran, Kenya, Peru, Sierra Leone, South-Africa, the 
United Republic of Tanzania, Uruguay, Venezuela and the Dominican Republic) WIPO, as a UN agency, 
should be “fully guided by the broad development goals that the UN has set for itself, in particular the 
Millennium Development Goals” and take due account of all the pro-development provisions in the TRIPS 
Agreement and subsequent decisions such as the Doha Declaration on the TRIPS Agreement and Public 
Health. Argentina and Brazil took the initiative to launch the Development Agenda in 2004 and their 
proposal was rapidly co-sponsored by 13 developing countries. Notably, eight Latin American countries 
support the proposed Development Agenda. The original proposal explains that although significant 
scientific and technological progress has been made over the last century a knowledge gap as well as a 
digital divide continues to separate the wealthy nations from the poor. They argue that it is of importance 
not to see intellectual property protection as an end in itself, nor to treat all countries alike in the 
harmonization of intellectual property laws, but to take due account of different levels of socio-economic 
development. The FoD proposal identified several ways to achieve this objective. For instance it proposed 
to develop a treaty on access to knowledge and technology, amending the WIPO Convention to incorporate 
the development dimension and reforming WIPO norms and practices, including the development of 
principles and guidelines for norm-setting activities. It also encourages wider civil society participation in 
the WIPO negotiation process. 
In June 2007 WIPO Members recommended, at a working level, to elevate to the WIPO General Assembly 
the adoption of 45 recommendations to achieve these development goals and to establish consequently a 
Committee on development and intellectual property. 
Source: Puentes, ICTSD, Volume VIII, No.1, March 2007. 
 
 
With respect to access to knowledge, WIPO members have inter alia also agreed to: 
consider the preservation of the public domain within WIPO’s normative processes and deepen 
the analysis of the implications and benefits of a rich and accessible public domain; take 
appropriate measures to enable countries to fully understand and benefit from different 
provisions, pertaining to flexibilities provided for in international agreements; make available 
advice on the implementation and operation of the rights and obligations and the understanding 
and use of flexibilities contained in the TRIPS Agreement; consider how to better promote pro-
competitive IP licensing practices, particularly with a view to fostering creativity, innovation and 
the transfer and dissemination of technology to interested countries; and explore IP-related 
policies and initiatives necessary to promote the transfer and dissemination of technology, to the 
benefit of developing countries. 
ECLAC – Project documents Collection Intellectual Property Rights and Sustainable Development: … 
25 
3. Access to medicines33 
The impact of IPRs, particularly patents, on public health policies and access to medicines has 
been one of the most debated issues to surface in the WTO in recent years. As we will see, with 
the adoption of the Doha Declaration on the TRIPS Agreement and Public Health, the WTO 
General Council Decision for the implementation of Paragraph 6 of that Declaration34 and the 
subsequent amendment of the TRIPS Agreement, the focus of the discussion has shifted away 
from the WTO to the regional and bilateral front and the influence of recent FTAs. As far as 
substance is concerned, the FTAs have added another form of protection to traditional patent 
rights that is relevant to access to medicines: exclusive rights for pharmaceutical test data 
submitted to regulatory authorities with the purpose of gaining marketing approval. As we will 
see in detail infra, TRIPS mandates the protection of data submitted for the registration of 
medicines against unfair commercial use of that information (thus allowing other fair and 
reasonable uses), while the FTAs have expanded this protection, baring almost any use of that 
information unless there is consent from the right holder. 
Prominent actors have voiced the concern that provisions on IPRs in FTAs that go 
beyond the TRIPS minimum standards (i.e. “TRIPS-plus” provisions) may have a serious impact 
on countries’ public health policies. A report prepared for US Rep. Henry A. Waxman forcefully 
concludes: 
“In 2001, the United States joined the international community in adopting the Doha 
Declaration, which recognized that trade agreements should not impede the efforts of developing 
countries to obtain essential drugs at affordable prices. Since then, the Bush Administration has 
negotiated multiple trade agreements with developing countries, including the CAFTA agreement 
now pending before Congress. Contrary to the principles of the Doha Declaration, the 
Administration has used these trade agreements to restrict the access of developing countries to 
low-cost generic drugs. By delaying generic drug approvals, extending patent terms, limiting 
compulsory licensing, prohibiting parallel importation, and otherwise restricting countries’ 
efforts to improve access to affordable drugs, the trade agreements undermine the safeguards 
outlined in the Doha Declaration. These agreements may offer advantages to multinational 
pharmaceutical companies, but they do so at a serious cost to public health in the developing 
nations” (United States House of Representatives, 2005). 
                                                     
33  See Roffe & Spennemann (2006). 
34 
 WT/L/540 of 2 September 2003.
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The concern, in brief, is that by signing TRIPS-plus obligations developing countries risk losing 
the very flexibilities they are granted through the TRIPS Agreement, the Doha Declaration and the 
Decision on Paragraph 6.  
The TRIPS Agreement, as detailed earlier, brought about a number of important changes in the 
area of patent law. First of all, it introduced the obligation to make patents available in all fields of 
technology, and for both products and processes.35 This makes it impossible for WTO Members to exclude 
or continue excluding, pharmaceutical products from patentability. The Agreement also obliges Members 
to consider patents without discrimination as to the place of invention, the field of technology or whether 
the products are imported or produced locally.36 The latter raises questions on the flexibility countries now 
have to establish “local working” requirements for patents (providing compulsory licensing or revocation 
of the patent if the protected product is not produced locally but imported).37  
A. The flexibilities in TRIPS: the case of compulsory licensing 
The TRIPS Agreement leaves WTO Members some discretion for the design of their national patent laws. 
In particular, the following features are relevant to public health and access to medicines. The TRIPS 
Agreement: 
• Leaves Members the freedom to define whether they will apply a strict criterion of 
patentability. This is an important tool in preserving a large public domain for follow-on 
research and the promotion of competing products to help bring down prices; 
• Contains no obligation to make patents available for new uses of known patented products 
(“second uses”).38 This may be a way of avoiding the “evergreening” of patents by seeking an 
additional full patent term for the same product;39 
• Contains no obligation to prohibit price controls on patented products; 
• Authorizes the control of IPR abuses through competition laws and policies, in particular in 
licensing agreements;40 
• Allows for exceptions, under certain conditions, to the exclusive rights conferred by a 
patent.41 One relevant exception in the public health field is the early working or regulatory 
(“Bolar”) exception, discussed above (see chapter 1);  
• Allows Members to freely determine the substantive grounds for the issuance of compulsory 
licenses;42 
• Authorizes Members to determine their own system of IPR exhaustion (national, 
regional, or international). Through an international exhaustion regime, developing 
countries may facilitate parallel imports of low-priced drugs from abroad; 
                                                     
35 
 See Article 27.1, TRIPS Agreement. 
36
  Article 27.1, TRIPS Agreement. 
37
  See UNCTAD-ICTSD (2005), Chapter 25: Patents: Non-voluntary Uses (Compulsory Licenses) 
38
  For instance, Sildenafil (Viagra) was first patented by Pfizer to treat heart disease. After finding out that it also served to treat 
impotence, Pfizer filed a second patent for this new use of the same drug. This second patent has been invalidated in some 
countries because of lack of novelty or because it was found obvious. See:http://www.lockeliddell.com/files/News/ab9ebdd4-
621f-4432-a383-1cae37df9ea1/Presentation/NewsAttachment/c5a9d67e-bdd9-4c7e-97e9-
1d6efb6314dc/Andrews_Pfizers%20Viagra%20Pate nt.pdf and http://mb.rxlist.com/rxboard/viagra.pl?noframes;read=183. 
39
  Article 15.8.1(b) of the US – Oman FTA: Each party expressly “confirms that it shall make patents available for any new uses for, 
or new methods of using, a known product, including new uses and new methods for the treatment of particular medical 
conditions”. See http://www.ustr.gov/assets/Trade_Agreements/Bilateral/Oman_FTA/Final_Text/asset_upload_file715_8809.pdf.   
40 
 See Articles 8.2, 40, TRIPS Agreement. 
41 
 See Article 30, TRIPS Agreement. 
42 
 See Article 31, TRIPS Agreement 
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• Leaves each Member to employ exclusive or non-exclusive rights (i.e. through rules 
on unfair competition) to provide protection for pharmaceutical test data submitted to 
regulatory authorities for marketing approval purposes.43 There is an important 
difference between these two approaches, as discussed below.  
These TRIPS flexibilities were reaffirmed in the Doha Declaration on the TRIPS 
Agreement and Public Health in 2001: 
“In this [public health/access to medicines] connection, we reaffirm the right of WTO 
Members to use, to the full, the provisions in the TRIPS Agreement, which provide flexibility for 
this purpose”.44 
The WTO General Council Decision of 30 August 2003 on the Implementation of Paragraph 6 of 
the Doha Declaration on the TRIPS Agreement and Public Health45 even extended the TRIPS flexibilities 
with regards to compulsory licensing: in essence, the 30 August Decision (Decision on Paragraph 6) 
waives the exporting country’s obligation under TRIPS Article 31(f) to use drugs produced under 
compulsory license predominantly for the supply of its own domestic market.46 It also waives the 
obligation of the importing Member under Article 31(h) to pay an adequate remuneration to the patent 
holder, where remuneration for the same product has already been paid in the exporting Member.47  
The issuance of compulsory licenses and the conditions under which they should be authorized 
have been an important chapter in the deliberations on the relationship between IPRs and access to 
medicines, and again on the use of flexibilities under TRIPS. This was again reaffirmed in the Doha 
Declaration on the TRIPS Agreement and Public Health. Paragraph 4 of the Doha Declaration 
acknowledges that:  
“…the TRIPS Agreement does not and should not prevent Members from taking 
measures to protect public health. Accordingly, while reiterating our commitment to the TRIPS 
Agreement, we affirm that the Agreement can and should be interpreted and implemented in a 
manner supportive of WTO Members’ right to protect public health and, in particular, to promote 
access to medicines for all.” 
Notwithstanding the Doha Declaration, the use of this TRIPS “flexibility” continues to be 
controversial. As recently as January 2007, the government of Thailand authorized the use of compulsory 
licensing to allow generic production of more than a dozen patented medicines unless companies 
substantially lower the price of their branded products. Previously, the government issued a compulsory 
license for the AIDS drug efavirenz with the intention of first importing a generic version of the medicine 
from India and later manufacturing it locally. This action by the Thai government has been challenged as 
“completely unprecedented anywhere in the world” and could result in international firms deciding against 
marketing their latest drugs in Thailand.48 
B. The use of flexibilities in the context of FTAs 
Free trade agreements include provisions on patents and data protection that go beyond the 
minimum standards established by the TRIPS Agreement. This is particularly the case of FTAs 
signed by Latin American countries with the US and notably also EFTA with respect to 
                                                     
43
  See Article 39.3, TRIPS Agreement. According to another view, this article does not leave Members the discretion to choose, but 
obligates them to provide for exclusive rights in the test data. For a discussion, see UNCTAD-ICTSD (2005), Chapter 28, Sec. 3. 
44 
 See paragraph 4 in fine of the Declaration on the TRIPS Agreement and Public Health. 
45 
 WTO document WT/L/540 of 2 September 2003. 
46 
 See paragraph 2 of the Decision. 
47 
 See paragraph 3, second sentence of the Decision. 
48 
 See “Thailand Continues the Battle for Cheaper Drugs”, Bridges, February-March 2007, page 17, at www.ictsd.org. 
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provisions dealing with data exclusivity. The main TRIPS-plus provisions with relevance for 
access to medicines, discussed below, relate respectively to: the patent restoration term; patentability 
criteria; compulsory licensing; parallel imports; regulatory exception; data exclusivity; and the linkage 
issue. 
a) Patent restoration term  
Under Article 33 of the TRIPS Agreement, the minimum term of patent protection is 20 years from the 
filing date. However, the period during which the patentee may actually take advantage of his monopoly 
rights may be affected in two ways. First, the patent grant may take several years, thus reducing the 
effective term of protection. Second, in order to market a patented pharmaceutical product, the right holder 
still needs to gain marketing approval from the responsible regulatory authority, which may also reduce the 
effective term in which the patentee can benefit from her monopoly rights. This is the rationale behind the 
FTA provisions that require an extension of the patent term in case the regulatory approval process delays 
the marketing of the patented product or process, and in cases where the granting of the patent has suffered 
administrative delays not attributable to the patent applicant. Such an outright extension of the patent term 
has been criticized as another manifestation of the TRIPS-plus nature of the FTAs that could delay the 
entry of competing medicines into the market. As discussed below, this trend is being corrected by the US 
Congress.  
b) Patentability criteria 
As opposed to the TRIPS Agreement, some FTAs, such as CAFTA-DR, contain a definition of what 
constitutes “industrial application”, referring to the US law concept of “utility” (Roffe, 2004), in the sense 
that the invention operates according to its intended purpose. This prevents parties from adopting narrower 
definitions, like the concept of “industrial applicability” as defined in European countries.49 The difference 
can be considerable. As opposed to the concept of “industrial applicability”, the “utility” approach permits 
the patentability of business models and purely experimental inventions that do not produce any technical 
effects and cannot be made or used industrially. This may result in the patenting of research tools needed 
for the development of competing products (UNCTAD-ICTSD, 2005). 
c) Compulsory licenses 
Contrary to the FTAs signed with Latin American countries, the US agreements with Australia, Jordan, 
Singapore and Vietnam limit the grounds for the use of compulsory licenses to cases of anti-trust remedies, 
public non-commercial use and national emergencies or other circumstances of extreme urgency.50 The 
FTAs with Latin American countries do not contain express limitations on the use of compulsory licenses 
and in side letters51 to the main agreements refer to the “WTO health solution”. The FTA with Chile, for its 
part, expressly refers to the terms of the Doha Declaration on TRIPS and Public Health in the Preamble to 
the IP Chapter. 
d) Parallel imports52 
                                                     
49
  Article 57 of the European Patent Convention: “Industrial application: An invention shall be considered as susceptible of 
industrial application if it can be made or used in any kind of industry, including agriculture”. See http://www.european-patent-
office.org/legal/epc/e/ar57.html. 
50  See e.g. Article 4, paragraph 20 of the USA - Jordan FTA 
51 
 Side letters are documents signed by the parties to the main agreement, with the purpose of clarifying certain aspects of the text. 
Technically they should have the same legal status as the main text. See a USTR document from July 2007 clarifying several 
aspects of an immigration understanding contained in a side letter to CAFTA at http://www.ustr.gov/assets/Trade_Agreements 
/Bilateral/ CAFTA/Briefing_Book/asset_upload_file650_13202.pdf.  
52 
 For a discussion on parallel imports and exhaustion of IPRs, see chapter 1, supra. 
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Under the US FTAs with Australia, Morocco and Singapore, the patent holder is authorized to 
prevent parallel imports through the use of contracts or other means.53 This limitation is not 
included in the FTAs with countries from the Latin American and Caribbean region. A US House 
of Representatives report prepared for Rep. Henry Waxman warns on this trend: 
“…making this policy permanent in trade agreements prevents countries that do not 
currently restrict parallel importation from reconsidering their national policies. Even in the 
United States there is great support for a form of parallel importation: both the house and the 
Senate have measures that would allow the importation of lower-priced patented drugs from 
Canada. The trade agreement language would make it difficult for the United States or other 
nations with current restrictions on importation to revisit their national policies.” 
e) The regulatory exception 
Article 30 of the TRIPS Agreement, as discussed elsewhere, authorizes Members to provide, 
under certain circumstances, limited exceptions to exclusive patent rights. One of these 
exceptions, as endorsed by a WTO panel (see chapter 1) and available in many domestic laws 
(Garrison, 2006), is the authorization for third party competitors to use patented subject matter to 
generate information required to support an application for marketing approval of a 
pharmaceutical or agricultural chemical product (also known as the “Bolar exemption”). The 
purpose of this exception is to accelerate the market entry of generic competitors immediately 
after the expiry of the respective pharmaceutical or agrochemical patent. As marketing approval 
may be time consuming, the generic producer is given the opportunity to submit a substance still 
under patent protection for approval during the patent term, to ensure regulatory approval is 
granted at the expiration of the patent term. Otherwise, delays in the approval of competing 
products would amount to a de facto extension of the exclusivity period accorded by the patent. 
This regulatory exemption is recognized in all of the US FTAs. 
f) Protection of undisclosed information 
Related to patent protection of pharmaceutical and chemical entities, Article 39.3 of the TRIPS 
Agreement prescribes that:  
“when requiring, as a condition of approving the marketing of pharmaceutical or of 
agricultural chemical products which utilize new chemical entities, the submission of undisclosed 
test or other data, the origination of which involves a considerable effort, shall protect such data 
against unfair commercial use. In addition, Members shall protect such data against disclosure, 
except where necessary to protect the public, or unless steps are taken to ensure that the data are 
protected against unfair commercial use”. 
The so-called pharmaceutical “research-based industry” considers the protection of data 
submitted for the registration of medicines to be of considerable economic magnitude. The 
rationale is that the manufacturer has invested, often heavily, in the research necessary to develop 
the relevant data (Meitinger, 2005),54 and where patent law fails to provide protection (e.g. 
because the active component was shortly to be out of patent, or because the drug was based on a 
combination of known substances used in a novel manner) the secrecy of the testing work would 
provide the only barrier against a generic competitor rapidly producing and registering an exact 
copy of the drug. From a public health perspective, however, the early entry of generic 
competition is also considered an important policy objective, whose realization is facilitated by 
                                                     
53 
 See e.g. Chapter 15, Article 15.9.4 of the USA - Morocco FTA, and Chapter 17, Article 17.9.4 of the USA - Australia FTA. 
54 
 It is argued that the estimated clinical costs per approved new drug exceed 50% of its total development costs.  
ECLAC – Project documents Collection Intellectual Property Rights and Sustainable Development: … 
 30 
regulations that allow health authorities to rely on existing test data to approve subsequent 
applications for generic products (UNCTAD-ICTSD, 2005).  
The original intention of the main advocates of TRIPS in the Uruguay Round was the 
establishment of an exclusive right in the form of an economic protection of test data for a given 
number of years. In a submission made by the US in 1990, which was joined by the EC and 
Switzerland, it was proposed that:  
“Contracting parties which require that trade secrets be submitted to carry out 
governmental functions, shall not use the trade secret for the commercial or competitive benefit of 
the government or of any person other than the right holder except with right holder’s consent, on 
payment of the reasonable value of the use, or if a reasonable period of exclusive use is given to 
the right holder” (cited by Watal, 2001). 
The Agreement did not fully recognize this new right but instead established that 
undisclosed information should be protected against unfair competition, leaving a number of 
uncertainties as to the appropriate implementation of this provision. The original intention, to 
recognise an exclusive protection of test data for at least five years from the date of approval of 
the pharmaceutical product, was first introduced in the North American Free Trade Agreement 
(NAFTA) and has been further elaborated and included in free trade agreements concluded by 
EFTA countries and the US with a number of developing countries. 
The US FTAs introduce this new regime, providing that once a company has submitted 
original data on a pharmaceutical product, regulatory authorities shall not permit competing 
producers to rely on that data for a period of five years from the date of marketing approval (ten 
years in the case of agricultural chemical products).55 This provision effectively requires generic 
producers to come up with their own test data, which very often is not economically feasible or 
may be considered unethical. It thus provides the data originator with a further period of 
exclusivity. It is important to note that this exclusivity may apply to non-patented pharmaceutical 
or agrochemical products, thus creating a new form of monopoly not required by TRIPS (Abbott, 
2004).56  
The CAFTA-DR agreement, as well as those more recently signed with Colombia, 
Panama and Peru, expressly maintains the possibility of requesting marketing approval at any 
time during the five-year period. Where the data originator requests domestic approval at the end 
of the five-year exclusivity period generated by his earlier request abroad, another term of 
protection of five years will be triggered, extending protection effectively to 10 years (15 in the 
case of agrochemicals) (Correa, 2000; Abbott, 2004). As discussed below, in a recent 
development in the US, the FTAs with Colombia, Panama and Peru have been revised to take into 
account many criticisms made as to the effects of these types of provision on access to medicines. 
g) Linkage between regulatory procedures and patent rights 
While the above observations may concern non-patented pharmaceutical and agrochemical 
products, most of the FTAs also contain a provision that can have an important impact with 
respect to patented pharmaceutical and agrochemical products. For instance, Chapter 15, Article 
15.10.3(a) of CAFTA provides that: 
“3. Where a Party permits, as a condition of approving the marketing of a 
pharmaceutical product, persons, other than the person originally submitting safety or efficacy 
information, to rely on evidence or information concerning the safety and efficacy of a product 
                                                     
55  See, e.g., Chapter 15, Article 15.10.1(a) of CAFTA 
56 
 The same author observes that such exclusivity renders illegal the registration of generic drugs for public non-commercial use. 
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that was previously approved, such as evidence of prior marketing approval in the Party or in 
another territory, that Party: 
(a) shall implement measures in its marketing approval process to prevent such other 
persons from marketing a product covered by a patent claiming the product or its approved use 
during the term of that patent, unless by consent or acquiescence of the patent owner; and  
(b) if the Party permits a third person to request marketing approval of a product during 
the term of a patent identified as claiming the product or its approved use, it shall provide that 
the patent owner be informed of such request and the identity of any such other person.” 
In other words, the decision by regulatory authorities to grant marketing approval is made 
dependent on the will of the patent holder, thus linking the separate realms of safety and efficacy 
regulations and patent rights. Besides the difficulties created for regulatory authorities to 
determine the validity of patents, this provision has been interpreted as potentially precluding 
governments’ options for using compulsory licenses to increase the availability of low-priced 
pharmaceutical products (Abbott, 2004). Since marketing approval is independent of patent law, 
the third party authorized to produce a patented product under compulsory license would arguably 
depend on the patentee’s consent or acquiescence for the actual marketing of the product 
(UNCTAD-ICTSD, 2005). Chile, in its FTA implementing legislation, has provided that once a 
compulsory license is issued, the associated test data may also be used. 
C. Recent developments in US policies 
On 10 May 2007, the terms of an agreement between Congress and the US administration on the 
pending FTAs with Colombia, Peru and Panama were made public. The agreement would allow 
the ratification of these FTAs provided that changes are incorporated on three counts, namely on 
basic labour standards, environmental issues and access to medicines. Of the latter, the agreement 
calls for amendments in five areas:  
a) Data exclusivity. It is suggested that in cases where data exclusivity for new chemical 
entities relies on marketing approval in the US, provided Colombia, for example, 
grants approval within six months of an application by a person that produced the 
original data, the five year exclusivity should begin when the drug was first approved 
in the US (a so-called “concurrent period”). This important change takes care of one 
of the criticisms of the CAFTA-DR, referred to above, of extending the exclusivity 
period for an added five years; 
b) Patent extensions. Parties “may” extend the term of a patent to compensate for 
unreasonable delays in the patent or marketing approval process. In other words the 
mandatory obligation to compensate for those delays is transformed into an option for 
the parties. But the FTAs also provide that a party should endeavour to process patent 
and marketing approval applications expeditiously, with a view to avoiding 
unreasonable delays. 
c) Linking drug approval to patent status. The agreement here is straightforward, calling 
for the FTA texts to be amended so that there is no “linkage” between drug 
regulatory agencies and patent issues, and in particular no requirement that the drug 
regulatory agency withhold approval of a generic until it can certify that no patent 
would be violated if the generic were marketed. However, the agreement does 
prescribe that a party would be required to provide procedures and remedies (judicial 
or administrative proceedings, including injunctions), for adjudicating expeditiously 
any patent infringement concerning validity or disputes that arise with respect to a 
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product for which marketing approval is sought. Transparency in these processes is 
also advocated. Parties to the FTA could choose to implement the “procedures and 
remedies” obligation through a linkage system, but in these cases they should make 
available: i) an expeditious administrative or judicial procedure to challenge the 
validity or applicability of the patent (so as to break the ex-officio “link” in 
appropriate cases), and ii) effective rewards for successfully challenging the system 
as already provided in US law. In other words, the agreement tries to balance the 
rights of patent holders with opportunities for generic producers to challenge patented 
products that might impinge the entry into the market of competing products. 
d) Side letter on Public Health. As mentioned previously, some of the FTAs include side 
letters that refer to the Doha Declaration on TRIPS and Public Health. The agreement 
prescribes that they should be made part of the text of the FTA by i) affirming the 
parties commitment to the Doha Declaration; ii) clarifying that it does not prevent the 
parties from taking measures to protect public health; and iii) including an exception 
to the data exclusivity obligation for measures to protect public health in accordance 
with the Doha Declaration. 
e) Economic Development. An important final element of the agreement is the 
provision that the FTA could include a provision calling for a periodic review of the 
implementation and operation of the IP chapter, and giving the parties an opportunity 
for further negotiations. The parties could agree to consider, inter alia, whether any 
changes in the level of economic development in the territory of the other party 
would support amendments to the IP chapter. 
These developments are a sign of an important shift in US policies, that in many respects 
takes into account the criticisms faced by FTAs on account of their impact on the use of TRIPS 
flexibilities and on their actual impact on public health. The agreement of May 2007 has featured 
in revisions to the FTAs signed with Peru and Panama and ultimately with Colombia. The revised 
treaties, compared to those signed by CAFTA-DR, provide for additional flexibilities in the 
implementation of the FTAs. A major issue for those countries will be the proper use of the 
policy space left open by the new versions of these agreements. A further line of enquiry could be 
the possible implications of this new deal on third countries already party to an FTA with the US, 
as in the cases of CAFTA and Chile. 
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4. Genetic resources: biotechnological 
inventions, genetic resources, 
traditional knowledge  
Access to genetic resources and its relationship with IP has been a controversial aspect in 
multilateral deliberations, particularly in the WTO and WIPO. At the root of the controversy is 
the contentious provision of the TRIPS Agreement that:  
“Members may also exclude from patentability: plants and animals other than 
microorganisms, and essentially biological processes for the production of plants or animals 
other than non-biological and microbiological processes. However, Members shall provide for 
the protection of plant varieties either by patents or by an effective sui generis system or by any 
combination thereof”. (Article 27.3 b) 
Article 27.3(b) of TRIPS describes inventions that Members may exclude from 
patentability while, at the same time, specifically obliging Members to protect microorganisms 
and certain biotechnological processes. The final drafting of this provision reflects differences 
and uncertainties among countries over the scope of protection to be given to such inventions and 
the concerns regarding the patentability of life forms. The Agreement also provides for a review 
of this provision, which has become one of the key issues currently under consideration in the 
WTO Council for TRIPS.  
In the review process of Article 27.3 (b), developing countries, in particular, have 
presented their views on the possible implications of this provision with respect to the protection 
of living organisms and on the need to reconcile TRIPS with the Convention on Biological 
Diversity (CBD). 
TRIPS leaves flexibility for Members to adopt different approaches on the patentability 
of inventions relating to plants and animals, but requires the protection of microorganisms – 
though, as with other terms in TRIPS, such as the concept of invention itself, the meaning of 
microorganism is not defined, leaving some space for flexibility. TRIPS also obliges Members 
to introduce some kind of protection for “plant varieties” which most developing countries did 
not protect before the adoption of the Agreement. This obligation “has raised concerns in some 
of those countries about the impact of IPR protection on farming practices (particularly the re-
use and exchange of seed by farmers), genetic diversity, and food security)” (UNCTAD-
ICTSD, 2005). 
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TRIPS does allow for the exclusion from patentability of “plants and animals” in general. 
Consequently, Members may exclude plants as such (including transgenic plants), plant varieties 
(including hybrids), as well as plant cells, seeds and other plant materials. They may also exclude 
animals (including transgenic) and animal races. For example, the European Directive,57 in line 
with TRIPS, excludes from patentability: plant and animal varieties; and essentially biological 
processes for the production of plants and animals.  
The TRIPS Agreement, however, states that Members “shall provide for the protection of 
plant varieties either by patents or by an effective sui generis system or by any combination 
thereof”.  
The option of patent protection is straightforward. But the Agreement leaves the content 
of “an effective sui generis regime” open to interpretation. It might suggest the breeder’s rights 
regime, as established in the UPOV Convention (International Union for the Protection of New 
Varieties of Plants) (see Box 3 below), that could have been the intention of some negotiators 
during the Uruguay Round, but the text does not contain any such references. The possibility is 
also open to combine the patent system with a breeders’ rights regime, or, indeed, to develop 
other “effective sui generis” forms of protection.  
The remainder of this chapter will be devoted to analysis of the major developments that 
have taken place in the deliberations in WTO and WIPO on these issues, focussing on the review 
of the biodiversity provision of the TRIPS Agreement, the protection of life forms, the 
relationship between TRIPS and the CBD and the debates surrounding the protection of 
traditional knowledge. We will return to examine further how the FTAs concluded between the 
US, EU and EFTA on one side, and a number of developing countries on the other, relate to these 
questions.  
A. Deliberations in WTO 
With respect to genetic resources, the most relevant IP issue has been the relation between the 
TRIPS Agreement and the CBD and, in this context, discussions on the disclosure of origin of 
genetic resources and associated traditional knowledge (TK) in patent applications. The debates 
on disclosure of origin have revolved around several positions, ranging from solutions through 
contracts, to amendments of specific international agreements. As detailed in this section and the 
following, four concrete proposals have been tabled in the WTO and WIPO respectively.   
The built-in mandate in the TRIPS Agreement to review Article 27.3(b) was expanded by 
the Doha Ministerial Declaration to include the relationship between the TRIPS Agreement and 
the CBD and the protection of TK and folklore.58 Therefore, discussions on biodiversity issues in 
the WTO have centred on these three issues, with most attention given to the relationship between 
TRIPS and the CBD. Of the latter, the disclosure of origin of genetic resources and associated TK 
in patent applications to combat their misappropriation has been the central issue at hand. 
 
                                                     
57 See the European Directive on legal protection of biotechnological inventions of 1998 (98/44/EC). 
58  Paragraph 19 of the Doha Ministerial Declaration states: “We instruct the Council for TRIPS, in pursuing its work program 
including under the review of Article 27.3(b), the review of the implementation of the TRIPS Agreement under Article 71.1 and 
the work foreseen pursuant to paragraph 12 of this Declaration, to examine, inter alia, the relationship between the TRIPS 
Agreement and the Convention on Biological Diversity, the protection of traditional knowledge and folklore, and other relevant 
new developments raised by Members pursuant to Article 71.1. In undertaking this work, the TRIPS Council shall be guided by 
the objectives and principles set out in Articles 7 and 8 of the TRIPS Agreement and shall take fully into account the development 
dimension.” See WTO document WT/MIN(01)/DEC/1. 
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a) The Review of Article 27.3(b): the various issues under 
consideration, including the protection of life forms 
As mentioned earlier, Article 27.3(b) contains a review process that actually began in 1999. The 
debates have revolved around several issues, one of them being the relationship between TRIPS 
and the CBD, which has since become almost the sole biodiversity issue discussed in the WTO. 
Other matters discussed in the review process include:  
• What are effective sui generis systems for the protection of plant varieties;  
• Whether concepts such as microorganisms, plants and animals should be defined; 
• The protection of traditional knowledge associated with genetic resources; and  
• Whether the exceptions related to life forms should be eliminated, qualified or 
strengthened.  
One of the most heated debates has been on the latter issue of exceptions to life forms, 
between those for and against providing patent protection for inventions based on plant and 
animal life. Positions range from proposals to amend the TRIPS Agreement in order to prohibit 
the patenting of any life forms, including microorganisms and non-biological and microbiological 
processes,59 to those that propose extending patent protection to all inventions, including plants 
and animals. India and Kenya, the latter generally speaking on behalf of the African Group of 
countries, have been the main exponents of the case against patent protection of life forms, 
whereas Singapore and the US have stated that they consider exceptions to patentability 
unnecessary. Australia, Canada, China, the Republic of Korea and the EC have put forward 
arguments in favour of preserving Article 27.3(b) as it is. In other words, the preservation of 
Article 27.3(b) would allow the patentability of all types of life forms, but at the same time enable 
WTO Members to except plants, animals and essentially biological processes from patent 
protection. As noted above, this is precisely what the European Directive on the legal protection 
of biotechnological inventions does. The Directive recognizes the patentability of 
biotechnological inventions that are new, involve an inventive step and capable of industrial 
application, even if they concern a product consisting of or containing biological material or a 
process by means of which biological material is produced, processed or used. It excludes plants 
and animal varieties and essentially biological processes but recognizes the patentability of 
inventions related to plants or animals “if the technical feasibility of the invention is not confined 
to a particular plant or animal variety”. It also allows for the patentability of “inventions which 
concern a microbiological or other technical process or a product obtained by means of such 
process”.60  
The main arguments against the patentability of plants and animals have been that:61 
• Living things should not be patentable because they are discoveries and not proper inventions;  
• The differentiation between plants and animals on the one hand and microorganisms on the 
other is artificial;  
• Patenting of life forms is in itself unethical;  
• There are implications for access to, and the cost of, the re-use and exchange of seeds by 
farmers as well as displacement of traditional varieties and depletion of biodiversity;  
                                                     
59
 See WTO document IP/C/W/404 of the African Group of June 2003. 
60 
 Articles 3 and 4 of Directive 98/44 of 6 July 1998. 
61
 See WTO document IP/C/W/369/Rev.1. 
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• Excessively broad patents may be granted, which do not fully meet the criteria for 
patentability;  
• The associated costs for the revocation of such patents;  
• Current international agreements protect the interest of innovators but do not adequately 
protect the countries and local communities that supply the genetic material and traditional 
knowledge. 
On the other hand, the main arguments favouring the patentability of plants and animals 
expressed in the context of WTO deliberations are that:62 
• With respect to ethical concerns, Article 27.2 of the TRIPS Agreement would adequately take 
into account ethical concerns as far as patent law is concerned;63  
• Biotechnological inventions, including plants and animals, should be accorded the same 
patent protection as inventions in other fields, to promote private sector investment in 
inventive activities and to contribute to solving problems in areas such as agriculture, 
nutrition, health and environment;  
• Patent protection for plants and animals facilitates the transfer of technology and the 
dissemination of state of the art research, by providing incentives to licensing and 
discouraging confidentiality and trade secrets arrangements;  
• Patent disclosure requirements can facilitate the operation of laws aimed at protecting public 
morality, health and the environment.  
b) The relationship between TRIPS and the CBD 
The issue of the relationship between the TRIPS Agreement and the CBD was mandated for 
discussion in the TRIPS Council by the Doha Ministerial Declaration. However, this relationship 
is also being discussed in parallel “dedicated consultations” as an outstanding implementation 
issue under the Doha Declaration and the Hong Kong Ministerial Declaration.64 The Hong Kong 
mandate – to intensify TRIPS-CBD consultations – has been carried out under the supervision of 
the Director General of the WTO, who has to report to the meetings of both the General Council 
and the Trade Negotiations Committee (TNC).  
The debates in the TRIPS Council are often seen as being of a more technical nature than 
those held in the “dedicated consultations”, which are rather seen as part of the broad political 
context of a package deal comprising different issues and interests at stake. The discussions 
revolve around the question of whether there is a conflict between TRIPS and the CBD. Given 
that TRIPS is an agreement recognizing private rights and permitting the appropriation of genetic 
                                                     
62 See WTO document IP/C/W/369/Rev.1 
63  TRIPS Article 27.2 states that: “Members may exclude from patentability inventions, the prevention within their territory of the 
commercial exploitation of which is necessary to protect ordre public or morality, including to protect human, animal or plant life 
or health or to avoid serious prejudice to the environment, provided that such exclusion is not made merely because the 
exploitation is prohibited by their law.” 
64 Paragraph 39 of the Hong Kong Ministerial Declaration states the following: “We reiterate the instruction in the Decision adopted 
by the General Council on 1 August 2004 to the TNC, negotiating bodies and other WTO bodies concerned to redouble their 
efforts to find appropriate solutions as a priority to outstanding implementation-related issues. We take note of the work 
undertaken by the Director-General in his consultative process on all outstanding implementation issues under paragraph 12(b) of 
the Doha Ministerial Declaration, including on issues related to the extension of the protection of geographical indications 
provided for in Article 23 of the TRIPS Agreement to products other than wines and spirits and those related to the relationship 
between the TRIPS Agreement and the Convention on Biological Diversity. We request the Director-General, without prejudice 
to the positions of Members, to intensify his consultative process on all outstanding implementation issues under paragraph 12(b), 
if need be by appointing Chairpersons of concerned WTO bodies as his Friends and/or by holding dedicated consultations. The 
Director-General shall report to each regular meeting of the TNC and the General Council. The Council shall review progress and 
take any appropriate action no later than 31 July 2006.” See WTO document WT/MIN(05)/DEC. 
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resources through the patenting of life forms, it is argued that it could run counter to the sovereign 
rights of countries over their resources, as provided for in the CBD. Additionally, it is also argued 
that this appropriation could conflict with one of the main objectives of the CBD, namely the 
“fair and equitable sharing of benefits arising out of the utilization of genetic resources”.65  
The CBD requires each contracting party to implement several measures in order to 
ensure the in-situ and ex-situ conservation of genetic resources. Additionally, it recognizes the 
authority of national governments to determine access to genetic resources, subject to national 
legislation. Under the CBD, access, where granted, shall be on mutually agreed terms and subject 
to prior informed consent of the contracting party providing the genetic resources and on the basis 
of benefit sharing arrangements. Box 2 provides a summary of the key features of the CBD as it 
relates to IPRs. 
BOX 2 
THE CBD 
The CBD provides that States have the “sovereign right to exploit their own resources” and that they will, 
“subject to its national legislation, respect, preserve and maintain knowledge, innovations and practices of 
indigenous and local communities embodying traditional lifestyles relevant for the conservation and 
sustainable use of biological diversity and promote their wider application with the approval and 
involvement of the holders of such knowledge, innovations and practices and encourage the equitable 
sharing of the benefits arising from the utilization of such knowledge, innovations and practices”. 
Additionally, the CBD states that each party “shall endeavour to create conditions to facilitate access to 
genetic resources for environmentally sound uses by other Contracting Parties”66…”on mutually agreed 
terms” and that such access “shall be subject to prior informed consent of the Contracting Party providing 
such resources”.67 Finally, those using the genetic resources shall share “in a fair and equitable way the 
results of research and development and the benefits arising from the commercial and other utilization of 
genetic resources with the Contracting Party providing such resources”.       




The relationship between TRIPS and the CBD has given rise to different opinions, 
ranging from those considering the two agreements to be compatible, to those considering that 
there is an inherent conflict between the two international agreements. This conflict has been 
associated with the possible granting of IPRs, based on or consisting of genetic resources, without 
observing the prior informed consent and benefit sharing obligations established by the CBD. The 
different views on the TRIPS-CBD relationship could be summarized as follows: a number of 
developed countries find no inconsistencies between the two treaties while several developing 
countries highlight the need to reconcile the two agreements, possibly by means of a formal 
revision of TRIPS. 
The main concern of developing countries is that TRIPS does not require patent 
applicants, whose inventions incorporate or use genetic material or associated TK, to comply with 
the obligations under the CBD. As pointed out, the CBD subjects access to genetic material to 
prior informed consent from, and equitable benefit sharing with, the party providing the genetic 
resources. Developing countries have repeatedly voiced concerns about possible misappropriation 
of their genetic resources by developed country patent applicants. 
                                                     
65  See CBD Article 1, “The objectives of this Convention, to be pursued in accordance with its relevant provisions, are the 
conservation of biological diversity, the sustainable use of its components and the fair and equitable sharing of the benefits arising 
out of the utilization of genetic resources, including by appropriate access to genetic resources and by appropriate transfer of 
relevant technologies, taking into account all rights over those resources and to technologies, and by appropriate funding”. 
66  CBD Article 15.2. 
67  CBD Article 15.5. 
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In general terms, in order to address these concerns, developing countries have proposed 
an amendment to TRIPS so as to require applicants for a patent relating to biological materials or 
associated traditional knowledge, to disclose, as a condition for obtaining the patent: (i) the 
source and country of origin of the biological resource; (ii) any related TK used in the invention; 
(iii) evidence of prior informed consent from the authorities under the relevant national regime; 
and (iv) evidence of fair and equitable benefit sharing under the relevant national regime. 
The opinion of supporters of the disclosure requirement, not only developing countries, is 
that such an obligation would reaffirm the principles of the CBD, particularly with respect to 
prior informed consent and equitable benefit sharing, but also in terms of the consistency that 
must exist between the access and transfer of technology relevant to biodiversity and IPRs as 
provided for in the CBD.68 The biggest differences between proponents of disclosure are with 
respect to the legal effects of non-disclosure. Broadly, some argue in favour of sanctions within 
the IP system (e.g. revocation of the patent) whilst others favour sanctions outside the IP system 
(e.g. punitive damages) which would leave the patent intact.  
The attempt to reinforce CBD obligations through TRIPS is opposed by a number of 
developed countries that see no conflict between TRIPS and the CBD. For example, in the view 
of the US, the proposed disclosure requirement is not an appropriate solution. It advocates that 
members should instead focus on national solutions outside the IP system, which directly address 
the specific issues of prior informed consent, equitable benefit sharing and erroneously granted 
patents. They suggest that countries could, inter alia, promote the use of organized databases to 
help examiners assess prior art in patent filings, require that information concerning patentability 
be provided and use post-grant opposition or re-examination systems as an alternative to 
litigation.69  
Most importantly, the US has promoted the use of contracts between the authorities 
administering the genetic resources and those interested in using them (e.g. bioprospectors and 
researchers), thus fulfilling the requirement for prior informed consent. Additionally, contracts 
could regulate other matters, such as the transfer of benefits, the mandatory disclosure of relevant 
information (including the contract) if the invention is patented, and periodical reports on the use 
of the genetic resources. As we will see, this has been considered an adequate approach in the 
FTAs between the US and, respectively, Colombia and Peru (see box 4 below). 
Specific proposals made on disclosure requirements in the WTO 
Norway has submitted a proposal in the WTO supporting an amendment to the TRIPS Agreement 
by introducing a mandatory obligation to disclose the origin of genetic resources and TK in any 
patent application, be it national, regional or international.70  
The obligation would consist of disclosing the “supplier country (and the country of 
origin, if known and different) of genetic resources and traditional knowledge”, and “if the 
country of origin is unknown, that fact must be disclosed”. This would also apply to TK, even if it 
were not directly related to genetic resources. It should be noted that the CBD deals with only the 
                                                     
68
  Article 16.2 of the CBD provides: “Access to and transfer of technology referred to in paragraph 1 above to developing countries 
shall be provided and/or facilitated under fair and most favorable terms, including on concessional and preferential terms where 
mutually agreed, and, where necessary, in accordance with the financial mechanism established by Articles 20 and 21. In the case 
of technology subject to patents and other intellectual property rights, such access and transfer shall be provided on terms which 
recognize and are consistent with the adequate and effective protection of intellectual property rights. The application of this 
paragraph shall be consistent with paragraphs 3, 4 and 5 below”. 
69
  See IP/C/W7469 (13 March 2006). 
70 
 See WTO document WT/GC/W/566, TN/C/W/42 and IP/C/W/473 of 14 June 2006, submitted to the General Council, the TNC 
and the TRIPS Council. 
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TK associated with genetic resources. Applicants would also be obliged to disclose whether prior 
informed consent had been obtained.  
In Norway’s view, the amendment would provide that patent applications should not be 
processed unless the required information has been submitted. However, conversely to the 
approach of developing countries, non-compliance with the disclosure obligation discovered post-
grant would not affect the validity of the patent. According to Norway the disclosure requirement 
would not constitute a substantive patent criterion. In this context, TRIPS would be amended by 
the introduction of a new provision in the Agreement following the general provision on 
disclosure requirements (Article 29).71 Moreover, Norway also supports making corresponding 
amendments to both the Patent Cooperation Treaty (PCT) and the Patent Law Treaty (PLT) in the 
framework of WIPO.  
As with Norway, a group of developing countries, the most active demandeurs of the 
disclosure requirement, submitted a proposal in the WTO in July of 2006.72 This proposal, 
cosponsored by Brazil, China, Colombia, Cuba, Ecuador India, Pakistan, Peru, South Africa, 
Thailand, Tanzania and Venezuela, also suggests incorporating a new article after the general 
disclosure requirement provision (a new TRIPS Article 29bis). According to this proposal, the 
disclosure requirement should include: 
• An obligation to disclose the country providing the biological resources (a broader 
concept than genetic resources) and/or associated traditional knowledge;  
• From whom in the providing country the resources were obtained, and, as known 
after reasonable enquiry, the country of origin;  
• Information of evidence of compliance with legal requirements in the providing 
country for prior informed consent for access and fair and equitable benefit-sharing 
arising from the commercial or other utilization of such resources and/or associated 
traditional knowledge. 
Contrary to the Norwegian proposal, the legal effects of non-disclosure would be that the 
request for application would not be further processed, and that patents would be revoked or 
rendered unenforceable when the applicant knowingly (or having reasonable grounds to know) 
failed to comply with the obligation.    
Two other proposals for disclosure requirements have been submitted in WIPO, by 
Switzerland and the EC respectively, as discussed below.   
c) The protection of traditional knowledge and folklore 
Finding solutions to the protection of traditional knowledge is not straightforward. Dutfield 
identifies two main forms of protection: positive and defensive. 
“Positive protection refers to the acquisition by the TK holders themselves of an IPR 
such as a patent or an alternative right provided in a sui generis system. Defensive protection 
refers to provisions adopted in the law or by the regulatory authorities to prevent IPR claims to 
knowledge, a cultural expression or a product being granted to unauthorized persons or 
organizations” (Dutfield, 2006).  
                                                     
71
  Article 29: “1. Members shall require that an applicant for a patent shall disclose the invention in a manner sufficiently clear and 
complete for the invention to be carried out by a person skilled in the art and may require the applicant to indicate the best mode 
for carrying out the invention known to the inventor at the filing date or, where priority is claimed, at the priority date of the 
application. 2. Members may require an applicant for a patent to provide information concerning the applicant’s corresponding 
foreign applications and grants”. 
72
  See WTO document WT/GC/W/564, TN/C/W/41 and IP/C/W/474 of 5 July 2006, submitted to the General Council, the TNC and 
to the TRIPS Council. This proposal, as of June 2007, has received the support of the African Group. 
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The discussions in WTO have principally revolved around “defensive protection”. As we 
will analyze below, the deliberations in WIPO have been more comprehensive in nature and with 
greater emphasis on forms of “positive protection”. 
As detailed above, the debate in the WTO is tied to the relationship between TRIPS and 
the CBD, focusing on amendments to TRIPS in order to incorporate a requirement to disclose the 
use of traditional knowledge in patent applications. A question that has surfaced in the WTO 
regarding patents that comprise traditional knowledge is that of countries that do not recognize 
TK transmitted orally or through use outside their jurisdictions when considering the novelty of 
an invention (e.g. US and Japan). Because this information is often not documented, examiners 
would not be aware of it when examining a patent application. 
Approaches that have been suggested in the WTO to tackle the protection of traditional 
knowledge include the establishment of an “absolute” novelty criteria (as opposed to a “relative” 
criteria), by which any prior use or publication, anywhere in the world, would bar the 
patentability of the invention. The development of databases has also been proposed to prevent 
the issuance of patents that rely on information that should have been considered during the 
examination of prior art. To this effect, Japan submitted a proposal in WIPO to consider the 
establishment of a database of genetic resources and TK.73 
Some of the counterarguments that have been advanced to the development of such 
databases have been that: 
• Databases would still not accommodate TK and prior art transmitted orally;  
• They would not account for equitable benefit sharing with communities and indigenous 
people who are the holders of TK;  
• The inclusion of TK in public databases would only increase the problem of biopiracy as the 
information would be easily accessible for further misappropriation, and: 
• Databases would have limited use because there would be no obligation to consult them.  
B. Deliberations in WIPO 
a) General developments 
Issues related to biodiversity in WIPO have been addressed mainly in the context of the 
Intergovernmental Committee on Intellectual Property and Genetic Resources, Traditional 
Knowledge and Folklore (IGC). Furthermore, issues related to biodiversity and genetic resources 
have also been broached to a lesser extent in the Standing Committee for the Law of Patents 
(SCP) in the context of negotiations on the SPLT, in the Working Group on Reform of the PCT, 
and finally, in the discussions on a WIPO Development Agenda (see Box 1 above).  
In the context of the Development Agenda, and in addition to the general discussions, the 
issues of genetic resources and TK have risen in two specific proposals made by developing 
countries. The first relates to the adoption of “an internationally binding instrument on the 
protection of genetic resources, traditional knowledge and folklore in the nearest future”. The 
second proposal relates to “work on any initiative intended to facilitate the implementation of 
technology-related provisions of Multilateral Environmental Agreements (MEAs), so as to ensure 
that countries where biological, traditional or other environmental resources originate from, 
participate in the process of research and development”.  
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  This document was also submitted in the TRIPS Council. See WTO document IP/C/W/472 of 13 June 2006. 
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Regarding the discussions on an SPLT in WIPO, the issues of genetic resources and the 
environment found their way into several articles under consideration in the Draft SPLT.74 For 
instance, concerning general exceptions, the draft provides that neither the treaty nor the 
regulations should limit the freedom of contracting parties to “take any action it deems necessary 
for the preservation of essential security interests or to comply with international obligations, 
including those relating to the protection of genetic resources, biological diversities [sic], 
traditional knowledge and the environment”.75 Regarding the grounds for refusal of a claimed 
invention, draft Article 13.4 would allow parties to “require compliance with the applicable law 
on public health, nutrition, ethics in scientific research, environment, access to genetic resources, 
protection of traditional knowledge and other areas of public interest in sectors of vital 
importance for their social, economic and technological development”. Finally, the draft provides 
for similar grounds for invalidation or revocation of a patent.76  
The US, Japan and the European Patent Office (EPO),77 submitted a joint proposal to the 
SCP in May 2004, suggesting discussions focus on reaching an agreement on an initial four issues 
(definition of prior art, grace period, novelty and non-obviousness/inventive step) before the SCP 
could then turn to discuss other issues such as those related to genetic resources.78 The proposal 
met with the forceful opposition of developing countries, who are seeking a more comprehensive 
approach to the treaty, which has lead to a stalemate in the SPLT negotiations at the time of 
writing.  
The discussions around the SPLT have thus been most controversial, particularly with the 
general opposition of developing countries to using the SPLT as a platform for further substantive 
harmonization of patent law. In many respects the initiative behind the WIPO Development 
Agenda finds its origin in the concerns arising from the SPLT discussions.  
b) The Intergovernmental Committee on Intellectual Property and 
Genetic Resources, Traditional Knowledge and Folklore (IGC) 
The IGC was established in 2000, after Colombia submitted a proposal (Vivas, 2001) during 
negotiations on the PLT,79 which sought to incorporate, among others, a requirement to “specify 
the registration number of the contract affording access to genetic resources and a copy thereof 
whereby the products or processes for which protection is sought have been manufactured or 
developed”.80 The proposal was supported by many developing countries and was rejected by 
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.
 See WIPO document SCP/10/2. 
75 See Articles 2.2 and 2.3 of the Draft SPLT. WIPO document SCP/10/2. 
76  See Article 14.3 of the Draft SPLT. WIPO document SCP/10/2. 
77  See WIPO document SCP/10/9. 
78  The proposal did mentioned discussion on disclosure requirements but did not take into account that the draft treaty included 
several other “public interest” provisions. 
79  The aim of the Patent Law Treaty (PLT) of 2002 is to harmonize and streamline formal procedures in respect of national and 
regional patent applications and patents, and thus to make such procedures more user-friendly. With the significant exception of 
the filing date requirements, the PLT provides maximum sets of requirements, which the Office of a Contracting Party may apply. 
This means that a Contracting Party is free to provide for requirements that are more generous from the viewpoint of applicants 
and owners, but are mandatory as to the maximum that an Office can require from applicants or owners. Source WIPO, 
http://www.wipo.int/treaties/en/ip/plt/summary_plt.html, as of 12 April 12, 2007. 
80  The proposal by Colombia was submitted to the Third Session of the Standing Committee on the Law of Patents, in September 
1999. It read: “1) All industrial property protection shall guarantee the protection of the country’s biological and genetic heritage. 
Consequently, the grant of patents or registrations that relate to elements of that heritage shall be subject to their having been 
acquired legally; 2) Every document shall specify the registration number of the contract affording access to genetic resources and 
a copy thereof where the goods or services for which protection is sought have been manufactured or developed from genetic 
resources, or products thereof, of which one of the member countries is the country of origin”. See WIPO document SCP/3/10 at 
http://wipo.int/meetings/en/details.jsp?meeting_id=3824. 
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most of the developed countries on the grounds that it “related to issues of substantive law and 
was therefore not appropriate for inclusion in the draft Treaty”.81 
With its mandate renewed for two years at the 2005 WIPO General Assembly, the IGC 
held its eleventh session in July 2007.82 To date, the IGC has discussed extensively the issues of 
traditional knowledge and traditional cultural expressions (TCEs or folklore) and has even 
considered detailed draft provisions on objectives and principles for the protection of TK and 
TCEs, with the view of adopting an international instrument.83 The nature of such an instrument 
is a major source of disagreement. The IGC has been deliberating for some years, most of all 
towards an outcome on the issues of TK and folklore. The outcome could take diverse forms, 
including a “binding international instrument or instruments; a non-binding statement or 
recommendation; guidelines or model provisions; authoritative or persuasive interpretations of 
existing legal instruments; and an international political declaration espousing core principles and 
establishing the needs and expectations of TCE/TK holders as a political priority”.84 
On the other hand, work on genetic resources has been lagging behind, with some 
preparatory progress made.85 Although developing countries favour an internationally legally 
binding instrument for the protection of genetic resources, the opinion in the IGC has been that 
the Committee should focus on the more advanced work on TK and TCE, while avoiding 
duplication with work carried out in the WTO and the CBD on the issue of genetic resources. For 
those developing countries that have made proposals in the context of the WTO there is an 
inherent preference to deal with these questions there, where any resultant commitments would 
have more “teeth” that those that might result from negotiations in WIPO. This in a way reflects 
the position adopted by developed countries during the Uruguay Round, who sought to move 
discussions on IP out of WIPO for consideration in the new WTO system.  
As mentioned earlier, Japan submitted a proposal to the IGC in April 2006 to consider the 
establishment of a database of genetic resources and TK.86 Japan saw an easily accessible 
database, which would be available to patent examiners in any country, as a tool to prevent the 
issuance of erroneous patents. By creating such a database, it us argued, examiners would not 
have to deal with countless documents on TK when performing searches; prior art transmitted 
orally could be documented; and the problems of providing documentation in accessible 
languages could be solved by attaching a summary, in a widely used language, to the documents 
written in foreign or indigenous languages.  
With respect to the disclosure requirement discussed in the context of the WTO, the EC 
submitted a proposal to the IGC on a mandatory disclosure of the country or source of origin of 
genetic resources.87 The proposal by the EC would apply to all patent applications, whether 
international, regional or national. Therefore, it would necessitate amendments to the PLT, the 
PCT and regional agreements, such as the European Patent Convention (EPC). The obligation 
                                                     
81  See Report of the Third Session of the SCP at http://wipo.int/edocs/mdocs/scp/en/scp_3/scp_3_11.doc. 
82  The 11th session of the IGC agreed to renew its mandate again and forwarded its decision to the 2008 General Assembly for 
approval. 
83  See WIPO/GRTKF/IC/11/5(c), 26 April 2007. 
84  See “Options for giving effect to the international dimension of the Committee’s work” (WIPO document 
(WIPO/GRTKF/IC/10/6). 
85  For instance, the IGC developed a database of contractual practices concerning intellectual property, access to genetic resources 
and benefit-sharing; a questionnaire on contracts and licenses; a Draft Technical study on Disclosure Requirements related to 
Genetic Resources and Traditional Knowledge (later forwarded to the Secretariat of the CBD); Draft Intellectual Property 
Guidelines for Access and Equitable Benefit-Sharing; and elaborated a complete document on issues relating to genetic resources 
and disclosure requirements in response to an invitation from the CBD. Further, Members have tabled specific proposals on the 
issue of protection of genetic resources and traditional knowledge 
86  See WIPO document WIPO/GRTKF/IC/9/13 at: http://www.wipo.int/edocs/mdocs/tk/en/wipo_grtkf_ic_9/wipo_grtkf_ic_9_ 
13.doc 
87  See WIPO document WIPO/GRTKF/IC/8/11 at: http://www.wipo.int/edocs/mdocs/tk/en/wipo_grtkf_ic_8/wipo_grtkf_ic_8_11.doc.  
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would consist of disclosing the country of origin of the genetic resources, if the invention was directly 
based on specific genetic resources, and if the country were unknown to the patent applicant then the 
source of origin would have to be disclosed. Additionally, the applicant would be obliged to disclose TK 
associated with the genetic resources, but there would be no obligation to disclose proof of prior informed 
consent and equitable benefit sharing. The information would be submitted in a simple, standardized form, 
and the patent offices would communicate the fact that there has been a disclosure to a centralized body 
(e.g. the Clearing House Mechanism of the CBD). In case an applicant does fail to comply with the 
obligation, by not submitting any information or by submitting incomplete information, then sanctions 
outside the patent system would be applied. Thus, there would be no effects on the validity of the patent.  
The EC proposal in the IGC differs from the proposal made by developing countries in WTO in 
three main respects. Firstly, it only requires disclosure of the origin of genetic resources, not of prior 
informed consent and equitable benefit sharing. Secondly, the EC opposes the revocation of the patent in 
the event that the origin is not disclosed. Instead, sanctions would be established outside the patent system, 
whereas developing countries favour the revocation of the patent. Thirdly, the EU advocates the 
amendment of the PCT, PLT and other treaties, but not the TRIPS Agreement. At present, the member 
countries of the EU are guided by the principle stated in the European Directive on biotechnological 
inventions: 
“Whereas if an invention is based on biological material of plant or animal origin or if it uses 
such material, the patent application should, where appropriate, include information on the geographical 
origin of such material, if known; whereas this is without prejudice to the processing of patent applications 
or the validity of rights arising from granted patents”.88 
The proposal by the EC has similar consequences and effects to that made by Norway in the 
context of the WTO with the aim of amending the TRIPS Agreement, as discussed above. 
In brief, and to underline the point, in comparing the corresponding parallel exercises in the WTO 
and in the WIPO-IGC, a general observation is that while WTO initiatives deal with “defensive” measures 
addressing possible misuses of genetic resources and associated TK, the WIPO exercise also tries to 
provide “positive” responses and options for TK protection. At the present juncture in negotiations, and in 
view of the intrinsic difficulties of providing universally acceptable solutions to the questions raised by the 
protection of TK in terms of “private rights”, defensive measures might prove a more realistic approach. A 
difficulty arising in this area is the need to reconcile the preservation of indigenous groups and their 
communal control of ancestral knowledge and practices, on the one hand, whilst granting exclusive 
property rights to that knowledge on the other. There are, however, scholars that consider this feasible 
through, for example, the recognition of a new sui generis system of IPRs:  
“Accommodating IPRs to this subject matter is primarily a learning process. As farmers adopt 
and familiarize themselves with the concepts of real and movable property rights, they might grow 
accustomed to the concept of property in intangible knowledge goods that underlies intellectual property 
systems. Because IPRs can potentially enhance farmers’ standing, bargaining powers, respect and 
incomes, these proposals seem likely to attract attention and support from rural communities” (Cottier & 
Panizzon, 2005). 
c) The Working Group on Reform of the Patent Cooperation Treaty 
(PCT) 
The Patent Cooperation Treaty is a WIPO global protection treaty, which makes it possible to 
seek patent protection for an invention simultaneously in each of a large number of PCT member 
countries by filing an “international” patent application. Such an application can be filed by 
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anyone who is a national or resident of a PCT contracting state. It is generally filed with the 
respective national patent office but the applicant can also do so through WIPO’s International 
Bureau in Geneva.  
In the context of the Working Group on the Reform of the PCT, Switzerland tabled a 
proposal in May 2003 on the disclosure of origin of genetic resources and traditional 
knowledge.89 The Swiss proposal consists of amendments to the PCT Regulations and the PLT to 
enable parties to these treaties to request the disclosure of source of genetic resources and/or TK 
incorporated in the invention, if the invention is directly based on those genetic resources and/or 
TK. The opportunity for disclosure would be within the international phase, and, in the event that 
disclosure was inadequate, domestic legislation would preclude the completion of the application 
at the national phase. The Swiss proposals were reiterated at the 2006 meeting of the Working 
Group,90 but were subsequently withdrawn at the 2007 meeting in order to avoid further delays to 
the work of the Group.91 They are being analyzed at the IGC. 
Regarding sanctions, Switzerland proposes that if the applicant does not comply with the 
national disclosure obligations, the application may be refused or considered withdrawn. In cases 
where the patent has already been granted, sanctions would not include revocation, unless the 
respective national law provided for revocation in fraudulent cases. 
Discussions in the PCT Working Group revolved around whether the Group was the 
appropriate forum to discuss the issue of disclosure, given that other fora such as the IGC, the 
TRIPS Council and the CBD were dealing with the same topic. Opinions differ as to how this 
question should be tackled within the context of the PCT. They range from discussing it as 
complementary to deliberations in other organizations, to considering that it is not appropriate to 
address the issue at all within the PCT.  
Notably, the Swiss proposals are consistent with amendments being sought in its 
domestic patent law. A new provision of the Swiss Patent Act would require patent applicants to 
disclose the source of a genetic resource, “insofar as the invention depends” directly on the 
resource. The Act also obliges the applicant, if they are unaware of the origin of the resource, to 
state so. This amendment to the Swiss law has met with the objection of the international industry 
group BIO for contravening the TRIPS Agreement by allegedly adding an additional 
technological-specific requirement to the patentability of biotechnological inventions and raising 
new potential grounds for the invalidity of patents.92  
C. The Free Trade Agreements (FTAs) 
As we have seen, the FTAs signal an important development in the evolution of the IP system. 
With respect to the issues discussed in this chapter, one can detect a tendency to include TRIPS-
plus provisions, among others, in the areas of patents and plant breeders rights. On the issue of 
the protection of genetic resources and TK, there have also been developments in the FTA texts, 
though not with the far reaching implications of some of the patent provisions. Organizations 
such as Oxfam International, however, have denounced “the double standards” in these 
agreements: 
                                                     
89
 See WIPO documents PCT/R/WG/4/13; PCT/R/WG/6/11; PCT/R/WG/7; and WIPO/IP/GR/05/INF/4. 
90  See Swiss Federal Patent Office available at http://www.ige.ch/E/jurinfo/j105.shtm, as of 12 April 2007. 
91  at http://www.wipo.int/edocs/mdocs/pct/en/pct_r_wg_9/pct_r_wg_9_8.doc. 
92  See ICTSD, Bridges BioRes, Vol.7, No. , 13 April 2007, available at: www.ictsd.org. 
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“While they extend the monopoly rights of large corporations, they offer no such 
protection for the vast amounts of knowledge held by farmers in developing countries” (Oxfam, 
2007). 
As mentioned above, in recent FTAs concluded between the US, EU and EFTA on one 
side and a variety of developing countries on the other, the 1991 Act of the UPOV Convention 
has been listed as one of the international treaties that parties should subscribe to in the near 
future as the modality of protection for plant varieties. Article 27.3(b) of the TRIPS Agreement, 
as discussed, obliges countries to prescribe protection of plant varieties either by patents, by an 
effective sui generis system of protection or by a combination of both. UPOV as a sui generis 
option is not referred to in the Agreement. The FTAs oblige countries to opt for the 1991 version of 




UPOV provides a framework for the protection of plant varieties. The Convention was first signed in 1961 
and revised in 1972, 1978 and 1991. It entered into force in 1968. It established the International Union for 
the Protection of New Varieties of Plants, based in Geneva and associated with WIPO. There are two 
versions of the Convention: UPOV 1978 and UPOV 1991. In both versions, the breeders’ right may be 
subject to two exceptions: the “breeders’ exemption” and the “farmers’ privilege”. The rights of breeders 
both to use protected varieties as an initial source of variation for the creation of new varieties and to 
market these varieties without authorization from the original breeder (the “breeder exemption”) is covered 
in both versions of the Convention. One difference is that the 1991 version states that the original breeder’s 
right also extends to varieties which are essentially derived from the protected one. The intention is that 
breeders should not be able to acquire protection too easily for minor modifications of extant varieties. This 
provision is also intended to ensure that patent rights and breeders rights operate harmoniously. 
In the 1978 version there is no reference to the right of farmers to re-sow seed harvested from protected 
varieties for their own use (often referred to as the “farmers’ privilege”). Thus countries that are members 
of the 1978 version are free, but not obliged, to uphold the farmers’ privilege. In this respect, the 1991 
version is more specific. Whereas the scope of the breeders’ right includes production or reproduction and 
conditioning for the purpose of propagation, governments can use their discretion to decide whether to 
uphold farmers’ rights. The Convention (Article 15) provides for an optional exception that allows parties 
“within reasonable limits and subject to the safeguarding of the legitimate interests of the breeder, [to] 
restrict the breeder’s right in relation to any variety in order to permit farmers to use for propagating 
purposes, on their own holdings, the product of the harvest which they have obtained by planting, on their 
own holdings, the protected variety or [an essentially derived] variety”. This means that parties under 
UPOV 1991 can continue to uphold the farmers’ privilege as long as their national plant variety system 
provides for it. If the national legislation does not feature provisions on the farmers’ privilege, this 
presumably means there is no such privilege and that farmers cannot re-sow harvested seed even on their 
own farms.  
Source: UNCTAD-ICTSD (2003). 
 
 
UPOV’s plant breeders’ rights regimes have been criticized on the grounds that they 
better respond to conditions prevailing in industrialized countries and that as such risk 
undermining the food security of communities in developing countries. This, according to 
activists in the NGO community, may occur as a result of: 
• Encouraging cultivation of a narrow range of genetically-uniform crops, including 
non-food cash crops, with the possible consequences that people’s diets will become 
nutritionally poorer and crops will be more vulnerable to outbreaks of devastating 
diseases; 
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• Limiting the freedom of farmers to acquire seeds they wish to plant without payment 
to breeders, and thereby impoverishing them further; 
• Restricting the free circulation of plant genetic resources, which is generally 
considered essential for the development of new plant varieties (UNCTAD-ICTSD, 
2003); 
• Increasing the market power of seed suppliers, pushing up the prices and enabling 
international firms to capture a larger segment of the profits from farming than poor 
farmers themselves (Oxfam, 2007). 
In FTAs with the US, countries undertake further commitments to make efforts to 
introduce legislation concerning the patenting of plants. For example, and although Chile is a 
member of the 1978 UPOV Convention, the FTA between Chile and the US provides for a “best 
endeavour” clause for both parties to undertake reasonable efforts, through a transparent and 
participatory process, to develop and propose legislation –within four years of the entry into force 
of the agreement– to provide patent protection for plants which are new, involve an inventive 
step, and are capable of industrial application. In the CAFTA-DR Agreement, plants and animals 
may be excluded from patentability, but any party that does not provide patent protection for 
plants by the date of entry into force of the agreement shall undertake all reasonable efforts to 
make such patent protection available. In addition, according to the same agreement, any party 
that provides patent protection for plants and animals as of, or after, the date of entry into force of 
the agreement shall maintain such protection. In other FTAs, such as the one between the US and 
Morocco, there is a straightforward obligation for the parties to grant patents to inventions on 
animals and plants. 
Another standard provision in US-forwarded FTAs that goes beyond TRIPS is that 
patents can only be revoked or cancelled on grounds that would have justified a refusal to grant 
the patent initially. Apparently then, the only causes for revocation or cancellation of a patent 
would be that the patent was not new, did not entail an inventive step or was not industrially 
applicable. However, other conditions of revocation have been incorporated in the different 
agreements, such as inequitable conduct, misrepresentation, the insufficiency of or unauthorized 
amendments to the patent specification, or nondisclosure of the invention. The question arises as 
to whether parties may incorporate substantial requirements at the domestic level on the 
disclosure of origin of genetic resources and associated TK. As explained above, the FTAs 
constitute a departure from the TRIPS Agreement but are built on its fundamental principles. As 
such, the disclosure of origin at the domestic level is in principle TRIPS compliant. Indeed, as 
mentioned the Swiss government is amending its patent law precisely to include such a 
requirement. In its recent report, Oxfam is of the view that in FTAs with the US, including 
CAFTA-DR, Peru and Colombia, “governments will no longer be able to reject a patent 
application because a firm fails to indicate the origin of a plant or show proof of consent for its 
use from a local community” (Oxfam, 2007). This assertion is reflected by a provision in the FTA 
between the US and Peru, that resembles the other treaties, with the exception of the FTA with 
Chile:  
“16.9. Each Party shall provide that a disclosure of a claimed invention shall be 
considered to be sufficiently clear and complete if it provides information that allows the 
invention to be carried out by a person skilled in the art, without undue experimentation, as of the 
filing date and may require the applicant to indicate the best mode for carrying out the invention 
known to the inventor as of the filing date.  
“16.10. With the aim of ensuring that the claimed invention is sufficiently described, each 
Party shall provide that a claimed invention is sufficiently supported by its disclosure if the 
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disclosure reasonably conveys to a person skilled in the art that the applicant was in possession 
of the claimed invention as of the filing date”.  
The extent to which these FTA provisions would inhibit the possibility of introducing 
disclosure requirements at the domestic level remains a matter of interpretation. But if that was 
their effect, as Oxfam suggests, there would be large political ramifications, especially for a 
country like Peru that has been a main proponent of amending TRIPS to accommodate a 
disclosure requirement. 
In another recent development, highlighted above, side letters were included in FTAs 
recently negotiated by the US with Colombia and Peru, respectively, recognizing the importance 
of TK and biodiversity, “as well as the potential contribution of traditional knowledge and 
biodiversity to cultural, economic, and social development”. The side letters reaffirmed the 
importance of obtaining prior informed consent and the equitable sharing of benefits. However, 
the understanding reached by the parties recognized that these objectives could be adequately 
addressed by mutually agreed contracts between users and providers. Box 4 reproduces the 
contents of the understanding with Colombia. 
 
BOX 4 
UNDERSTANDING REGARDING BIODIVERSITY AND TRADITIONAL KNOWLEDGE 
The Parties recognize the importance of traditional knowledge and biodiversity, as well as the potential 
contribution of traditional knowledge and biodiversity to cultural, economic, and social development. 
The Parties recognize the importance of the following: (1) obtaining informed consent from the appropriate 
authority prior to accessing genetic resources under the control of such authority; (2) equitably sharing the 
benefits arising from the use of traditional knowledge and genetic resources; and (3) promoting quality 
patent examination to ensure the conditions of patentability are satisfied. 
The Parties recognize that access to genetic resources or traditional knowledge, as well as the equitable 
sharing of benefits that may result from use of those resources or that knowledge, can be adequately 
addressed through contracts that reflect mutually agreed terms between user and providers. 
Each Party shall endeavor to seek ways to share information that may have a bearing on the patentability of 
inventions based on traditional knowledge or genetic resources by providing: 
- publicly accessible databases that contain relevant information; and  
- an opportunity to cite, in writing, to the appropriate examining authority prior art that may have a bearing 
on patentability. 




Besides reference to the issue of biodiversity and TK in side letters or 
understandings in the case of Colombia and Peru, not many FTAs have incorporated 
provisions on the protection of TK and folklore. However, Panama and Taiwan probably 
reached the most extensive provisions on this topic in their FTA, signed in 2003.93 The 
innovative provisions of this agreement refer to the protection of genetic resources, 
traditional knowledge and folklore. Although the provisions on these issues are quite 
strong, they do not provide for a requirement of disclosure of origin of genetic resources. 
Still, they provide a framework against misappropriation of genetic resources, for the 
legitimate access to genetic resources and for equitable benefit sharing. The parties to 
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 See text of the Panama - Taiwan FTA at http://2005.sice.oas.org/Trade/PanRC/PANRC_e.asp. 
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this FTA also agreed to develop a mechanism for the mutual recognition of plant 
varieties.  
Finally, the EU has concluded a very limited number of FTAs that include IP 
chapters, but has recently announced that it will engage in new negotiations. Of these, it 
is currently negotiating Economic Partnership Agreements with six regional groupings of the 
ACP countries. A proposal to one of these sub-groupings surfaced at the end of 2006 and 
included comprehensive IP provisions, including issues related to the CBD.  
According to this proposal, the parties would “underline the importance of acceding to 
the Convention on Biological Diversity (CBD) and agree that, in line with Article 46.2 of the 
Cotonou Agreement, the patent provisions of this Title and the Convention on Biological 
Diversity shall be implemented in a mutually supportive way”.94 As we can see, this issue is 
closely related to discussions in the WTO on the relation between the TRIPS Agreement and the 
CBD, and more specifically on whether there is a conflict between the two treaties or whether 
they can be interpreted in a mutually supportive way. The EU has also incorporated Article 8(j) of 
the CBD into its proposal: 
“Subject to their national legislation the Parties respect, preserve and maintain 
knowledge, innovations and practices of indigenous and local communities embodying traditional 
lifestyles relevant for the conservation and sustainable use of biological diversity and promote 
their wider application with the approval and involvement of the holders of such knowledge, 
innovations and practices and encourage the equitable sharing of the benefits arising from the 
utilization of such knowledge, innovations and practices”.95 
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 Ibid. 
ECLAC – Project documents Collection Intellectual Property Rights and Sustainable Development: … 
49 
5. Concluding observations  
A. The complexities of the IP landscape 
The incorporation of trade-related IP disciplines in the final outcome of the trade negotiations of 
the Uruguay Round signalled a major change in IP law making. The TRIPS Agreement not only 
incorporates IP within the international trading system but also introduces the concept of 
minimum standards of protection for each of the IP categories it deals with. The transformation 
brought about by TRIPS is particularly significant for developing countries. The “bottom up” 
approach to IP that characterised pre-TRIPS systems allowed each country to calibrate their IP 
regimes to their national interests.  
The TRIPS Agreement should not only be assessed on the basis of the changes it brought 
to the international IP architecture, but also by the legitimacy it has given to new initiatives with 
broad and profound consequences for further processes of IP harmonization. Building on the 
minimum standards principle of TRIPS, a new generation of bilateral and regional FTAs 
containing IP provisions have been signed in recent years, deepening the process of 
harmonization initiated by TRIPS.  
As observed in this paper, the WTO and WIPO have been the major institutions 
overseeing changes in the IP landscape at the multilateral level. However, in addition to the WTO 
and WIPO, there are a variety of organizations dealing with specific IP matters. Today, a number 
of intergovernmental bodies include IP-related questions in their work programmes, as is the case 
of the United Nations Education, Science and Culture Organization (UNESCO), the Convention 
on Biological Diversity (CBD) and other UN agencies, such as the United Nations Conference on 
Trade and Development (UNCTAD) and the United Nations Development Program (UNDP).  
The work of, respectively, the World Health Organization (WHO) and the Food and 
Agriculture Organization of the United Nations (FAO) has been of particular relevance. The 
WHO has engaged actively in questions related to IP and health, particularly in the report of its 
Commission on Intellectual Property Rights, Innovation and Public Health,96 and the follow-up 
work of its Intergovernmental Working Group on Public Health, Innovation and Intellectual 
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Property (IGWG).97 Most importantly, the 2007 World Health Assembly (the highest decision-
making body of the WHO) adopted Resolution 60.30 on Intellectual Property, Innovation and 
Public Health.98 The Resolution requests the WHO Director General: 
“[…] (2) to provide as appropriate, upon request, in collaboration with other competent 
international organizations, technical and policy support to countries that intend to make use of 
the flexibilities contained in the agreement on Trade-Related Aspects of Intellectual Property 
Rights and other international agreements in order to promote access to pharmaceutical 
products,1 and to implement the Doha Ministerial Declaration on the TRIPS Agreement and 
Public Health and other WTO instruments; […] 
“(4) to encourage the development of proposals for health-needs driven research and 
development for discussion at the Intergovernmental Working Group that includes a range of 
incentive mechanisms including also addressing the linkage of the cost of research and 
development and the price of medicines, vaccines, diagnostic kits and other health-care products 
and a method for tailoring the optimal mix of incentives to a particular condition or product, with 
the objective of addressing diseases that disproportionately affect developing countries.” 
For their part, FAO members spent a number of years negotiating an International Treaty 
on Plant Genetic Resources for Food and Agriculture (ITPGRFA) that finally entered into force 
in June 2004.99 Among others, the treaty provides that state parties should take measures: 
“to protect and promote Farmers’ Rights, including: (a) protection of traditional 
knowledge relevant to plant genetic resources for food and agriculture; (b) the right to equitably 
participate in sharing benefits arising from the utilization of plant genetic resources for food and 
agriculture; and (c) the right to participate in making decisions, at the national level, on matters 
related to the conservation and sustainable use of plant genetic resources for food and 
agriculture”. 
Given the crosscutting and interrelated nature of the issues under consideration, the 
involvement of so many institutions covering these matters highlights the challenges and 
complexities facing developing countries in managing and sustaining coherence in international 
and national IP policies. 
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 See text of the ITPGRFA at ftp://ftp.fao.org/ag/cgrfa/it/ITPGRe.pdf. In November 2001, the FAO Conference adopted the 
ITPGRFA, which came into force in 2004. Its “objectives are the conservation and sustainable use of plant genetic resources for 
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The paper has reviewed recent trends in the area of IP protection and their impact on 
sustainable development. We have focused on areas in which key developments have taken place, 
namely on access to knowledge, public health and genetic resources. These changes confirm the 
challenges ahead and the tasks developing countries will face in the coming years. Countries, 
particularly in the Latin American and Caribbean region, should be prepared to face these 
challenges. Among them, the implementation at the national level of new IP obligations 
constitutes a major challenge that offers, at the same time, opportunities for modernization and 
the establishment of more coherent approaches to policy making.  
B. Is there space for a creative implementation?100 
From the perspective of the demands of new commitments on the IP front that necessitate 
modernization of the national institutional base, policymakers could undertake the reform process 
in a dynamic way by not only recognizing and enforcing existing IPRs, namely from non-
residents, but by developing structures and institutions that make it possible for the IP system to 
contribute to the promotion of sustainable development goals. Such a dynamic implementation 
should respond to certain policy objectives and specific strategies. 
The implementation of IP obligations from a sustainable development perspective should 
consider the needs of the local environment. In undertaking these reforms the IP system should 
respond to objectives such as:  
• Striking an appropriate balance between rewarding innovation, creativity and 
investments on one hand, and access to knowledge and transfer of technology on the 
other; 
• Creating appropriate mechanisms to promote local innovation and creativity by 
instituting efficient and market-oriented incentives; 
• Using flexibilities with economic and social goals in mind; 
• Protecting the public interest in sectors of vital importance such as health, education 
and the sustainability of genetic resources; 
• Promoting coherent interaction with other regulatory or economic systems, including 
technology development strategies, competition, trade and FDI policies. 
In undertaking such reforms, countries should recall that they are not obliged to 
implement higher standards of protection and enforcement measures than those detailed in TRIPS 
and their respective FTAs (see for example, Article 15.1, CAFTA-DR). 
With respect to strategies for implementing these objectives, two aspects appear relevant 
here. The first relates to the use of the flexibilities that exist in the international system to design 
IP regimes that respond to the particular policy objectives of the country in question; and 
secondly, the related policies that can mitigate the potential costs of implementing a highly 
harmonized IP system in line with the parameters of more technologically developed societies. 
                                                     
100  
 See Roffe (2006). 
ECLAC – Project documents Collection Intellectual Property Rights and Sustainable Development: … 
 52 
a) Flexibilities within the IP system 
As discussed in this paper, the international IP system was rather liberal and adaptable in the 
period prior to TRIPS. The Agreement introduced fundamental changes to the international IP 
architecture that have intensified with the new generation of FTAs. However, these agreements, 
building on the existing international architecture, still leave room for the design of IP regimes 
that can accommodate the particular needs of a country. It is crucial to ensure there is awareness 
of the existence of these spaces and their appropriate uses. They refer to questions such as the use 
of existing mechanisms and public policy instruments that are not normally affected by the 
current international IP architecture, including the FTAs. For instance, and as reiterated above, 
the FTAs negotiated by Latin American countries do not exclude, with respect to compulsory 
licensing, the use of a patent without the authorization of the right holder.  
The Doha Declaration on the TRIPS Agreement and Public Health confirms the freedom 
of Members to establish their own regime for the exhaustion of IPRs, thus leaving countries with 
the possibility of choosing their domestic approach to parallel imports. Taking again the case of 
the FTAs negotiated by Latin American countries, the exhaustion of IPRs is not generally dealt 
with. This is not the case in the FTA between the USA and Morocco that allows the parties to 
limit parallel imports to cases where the patent owner has placed restrictions on importation by 
contract or other means. In brief, Latin American countries have in general retained the freedom 
in FTAs to design the most appropriate system of parallel importation. 
Even if the FTAs adopt stricter standards of protection and in some cases reduce the 
space for defining the patentability criteria,101 they still leave freedom for countries to define what 
constitutes an invention and to request a disclosure of origin in the case of inventions using 
genetic resources. This is also the case with respect to the use of exceptions and limitations, 
particularly in the case of patents and copyrights. However, in general, the exercise of exceptions 
in the case of patents (such as for teaching and research, commercial experimentation, prior use) 
(Garrison, 2003) needs to be explored further and used effectively by those countries modernizing 
their IP regimes. The same applies to exceptions and limitations in the case of copyright that are 
commonly used in developed countries (personal use, criticism, educational purposes) (Ruth 
Okediji, 2006). 
Within the IP system there are a number of other instruments that could be used more 
effectively in the implementation process to promote innovative capacities at the local level. If, 
for example, foreign right holders are the main beneficiaries of a national patent system, 
innovations of an incremental nature, such as those produced by and large in the Latin American 
and Caribbean region, might be protected by simpler systems such as utility models (Suthersanen, 
2006). Furthermore, other instruments of a non-proprietary nature could be explored, such as 
compensatory liability regimes and open source models. 
One of the most sensitive areas for the countries that have committed to FTAs that go 
beyond their TRIPS obligations is that related to pharmaceutical products. Specifically, these 
agreements introduce new standards for the marketing approval of new pharmaceutical products 
relating to the submission of undisclosed data concerning safety and efficacy. The FTAs contain 
detailed provisions on issues such as the prohibition of the use of such data without the consent or 
acquiescence of the first applicant for marketing approval, for at least five years from the date of 
approval. The FTAs also provide for a “linkage” between the marketing approval and the patent 
in the sense that a country is not permitted to provide marketing approval to any third party prior 
to the expiration of the patent term, unless by “consent or acquiescence” of the patent owner. 
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These provisions that tend to expand the protection of pharmaceutical products are 
enhanced by parallel obligations dealing with compensatory extensions of the duration of the 
patent in cases of undue delays in the administrative granting of the patent, or as a result of delays 
in the marketing approval of the products. The FTAs generally do not contain parameters for 
defining these compensatory extensions. This is a matter to be regulated domestically. For 
example, in the case of the US, from whom these provisions gain their inspiration, the restoration 
period is limited to five years in the case of administrative delays in the granting of the patent. 
With respect to “unreasonable curtailment of the patent term as a result of the marketing approval 
process”, there is a close relation in the USA between both extension terms: “the effective patent 
term including the restoration period may not exceed 14 years” (Roffe, 2004). 
These FTA provisions have attracted attention and have been the subject of criticism not 
only because of their TRIPS-plus nature, but because they make the exercise of flexibilities more 
problematic and run the risk of impairing access to medicines. They might also reinforce the 
dominant position of strong firms and make the entry of new competitors more difficult. Thus, 
there is a need to implement these provisions in a pro-competitive manner, in order to preserve a 
competitive environment and sanction possible abuses of dominant positions. In this area there is 
room for creative implementation.102  
A dynamic and pro-competitive implementation of new commitments should apply not 
only to health-related matters. Among the issues discussed in this paper, such as access to 
knowledge and genetic resources, the creativity in designing IP systems that would preserve 
flexibilities such as exceptions and limitations should be explored to the maximum. It should also 
be remembered that in the areas discussed throughout, as shown by recent developments in the 
US Congress with respect to health, the international system continues to evolve. This suggests 
the importance of permanently observing and understanding trends in this dynamic sphere of 
economic law.  
b) Modernizing IP-related regulatory regimes and institutions 
The implementation of new commitments should be undertaken in a coherent interaction with 
other regulatory regimes. We are dealing with broad and critical issues that could only be touched 
upon here. One of the main arguments advanced by advocates of changes in IP relations, 
particularly in the case of FTAs, is that they provide an opportunity for reform and 
modernization. One of the challenges faced by countries in the Latin American and Caribbean 
region is that in the area of IP these countries import systems of protection that have been tried 
and experienced in more advanced and legally sophisticated countries, which, among other 
features, have evolved systems of “checks and balances”. These systems are codified in 
legislation and regulations, and often in court interpretations (Abbott, 2006). 
The implementation process should be used as an opportunity for reform and 
modernization that would involve investment to ensure appropriate institutions and human 
resources. One area calling for reform relates to competition laws and policies that, in the case of 
developed countries, have taken  years to mature and evolve into more sophisticated systems that 
ensure the market operates under competitive conditions. Competition and IPRs should not be 
seen as contradictory but rather as interdependent elements. This should mean that the efficiency 
of the IP system is at stake whenever competition is distorted or artificially restrained. Only a 
                                                     
102  An interesting example of dynamic implementation is the case of Chile. In order to safeguard the public interest, the law 
provides that undisclosed information will not be protected in the events of: anticompetitive behavior; public health, national 
security, non-commercial public use, national emergency; when the pharmaceutical product is subject to a compulsory license; 
the product has not been commercialized in Chile within 12 months from the date of registration or sanitary approval in the 
country; the product has a registration or authorization in a foreign country of more than 12 months. 
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fully competitive market is likely to minimize the social costs resulting from the fact that IP 
protection cannot be adjusted to individual needs (UNCTAD, 1997).  
Probably more importantly, a well-structured IP system should interact coherently with 
the national innovation system and with the structures and institutions that support such a system. 
The implementation of high IP standards should be matched with a major effort to reinforce 
institutions and human resources related to science and technology, and creativity in general. This 
should be undertaken with the view that the weaker parties in FTAs should benefit from the IP 
system in ways that match the benefits received by their stronger trading partners.  
C. Final observations 
Until very recently, IP matters were perceived to be the domain reserved for legal experts and 
technocrats related to specific industrial sectors. The emergence of TRIPS and the inclusion of IP 
matters in FTAs have altered this perception. Civil society actors are active in assessing the 
implications of IPRs, particularly with respect to access to knowledge, medicines, nutrition and 
the appropriation of genetic resources.  
Considering the important socio-economic implications of the IP system, the reform and 
implementation of new IP obligations should constitute a participatory and coherent process 
where producers, competitors, and consumers all have a voice. At the government level, an inter-
ministerial approach should facilitate a wider consideration of the public interest and its different 
sensitivities and forms, particularly with respect to the impacts of IP policies on sustainable 
development priorities.  
A key challenge faced by countries in the Latin American and Caribbean region is in 
coping with the rapid evolution of ideas and concepts around IP and the understanding of their 
impact on development in general. This facet of the globalization process demands both a more 
coherent and holistic approach to international negotiations and the establishment of dynamic 
structures and competencies in economic diplomacy. Here there is an important role for regional 
organizations, such as the Economic Commission for Latin American and the Caribbean 
(ECLAC), to assist countries in pursuing coherent and informed policies in these interrelated 
areas of economic law. 
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